Cetylite  Industries,  Inc.                      
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
 
November 10, 2016 Page 1 of 48 Protocol v10.4 
 
 Cetylite Industries, Inc.  
1. STUDY PROTOCOL 
Title: A double-blind, partial cross-over, incomplete factorial study to 
assess the local anesthetic efficacy and safety of CTY-5339 
Anesthetic Spray (CTY-5339-A) when applied to the cheek mucosal tissue in normal volunteers 
Test Drugs: CTY-5339-A (14.0% benzocaine, USP, 2.0% tetracaine HCL, USP)  
CTY-5339-CB (14.0% benzocaine, USP) 
CTY-5339-P (Vehicle Spray) 
(1 metered spray will deliver ≈200 µL containing either benzocaine 28 
mg + tetracaine HCl 4 mg or benz ocaine alone 28 mg or vehicle.) 
Methods: Single-center, randomized, double- blind, partial cross-over, 
incomplete factorial design.  Pi n Prick and QST Heat (QST) will 
be utilized to assess efficac y.  Assessment of ECGs, pulse 
oximetry, and methemoglobinemia (blood co-oximetry) will be 
utilized to assess safety.  EC Gs and blood sampling will be 
performed at Baseline and after 1 hour of treatment. Pulse oximetry will be performed at Baseline and every 10 minutes through 1 hour after treatment. 
Sponsor Name and Address: Cetylite Industries, Inc. 9051 River Road Pennsauken, NJ 08110 
Protocol Identification: C-002 
Development Phase IIb: Proof-of-Concept Experimental Pain Model 
Company/Sponsor Representative: Stephen A. Cooper, D.M.D., Ph.D 117 Dalena Way Palm Beach Gardens, FL  33418    Phone:  973-710-6677 
Compliance Statement: The study will be conducted in accordance with the ethical 
principles that have th eir origin in the Declaration of Helsinki and 
with standards of current Good C linical Practice, as defined by 
Cetylite  Industries,  Inc.                      
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
 
November 10, 2016 Page 2 of 48 Protocol v10.4 
 
 the International Conference on Ha rmonization and all applicable 
FDA regulations. 
 
 
Date Version Comment(s) Author 
April 20, 2016  2.0 Draft S. Cooper 
April 27, 2016 3.0 Draft- (Hersh, Weisman, Doyle) S. Cooper 
May 2, 2016 3.1 Draft- (Hersh, Weisman, Doyle) S. Cooper 
May 7, 2016 4.0 Draft- (Hersh, Weisman, Doyle, Riley, Phelps) S. Cooper 
May 7, 2016 4.1 Draft- (Hersh, Weisman, Doyle, Riley, Phelps) S. Cooper 
May 7, 2016 4.2 Draft- (Hersh, Weisman, Doyle, Riley, Phelps) S. Cooper 
May 10, 2016 4.3 Draft- (Hersh, Weisman, Doyle, Riley, Phelps) S. Cooper 
May 16, 2016 4.4 Draft- (Hersh, Weisman, Doyle, Riley, Phelps) S. Cooper 
May 18, 2016 4.5 Draft- (Hersh, Weisman, Doyle, Riley, Phelps) S. Cooper 
May 25, 2016 4.6 Draft- Doyle Edits S. Cooper 
June 9, 2016 4.7 Minor Edits Prior to sign-off  Final Version S. Cooper/G.Doyle 
August 8, 2016 5.0 Incorporation of Amendment 1 Changes/Edits G. Doyle 
October 17, 2016 6.0 Incorporation of Pulse Oximetry and Stopping Rules S. Cooper/G. Doyle 
October 18, 2016 7.0 Correct version with latest  edits & Pulse Oximetry S. Cooper/G. Doyle 
October 19, 2016 8.0 Added FDA comment & IND Number S. Cooper 
October 19, 2016 9.0 Added Tegra comments S. Cooper 
November 3, 2016 10.0 Refinements to  QST Assessment, other minor edits/corrections S. Cooper/G. Doyle 
November 4, 2016 10.1 Refinements to  QST Assessment, other minor edits/corrections S. Cooper/G. Doyle 
November 8, 2016 10.2 Refinements to Baseline/Screen ing PPT and QST Assessments S. Cooper/G. Doyle 
November 9, 2016 10.3 Refinements to Baseline/Screen ing PPT and QST Assessments S. Cooper/G. Doyle 
November 10, 2016 10.4 Corrected Minor Inconsistencies G. Doyle 
 
Confidential Information 
The information contained within this re port is confidential a nd may not be used, 
divulged, published, or otherwise disclose d without the prior written consent of 
Cetylite Industries, Inc. 
Cetylite Industries, 
CONFIDENTIAL Amended (#3) Protocol C-002 IND# 117147
CTY-5339 Anesthetic Spray (CTY-5339-A) 
Signature Page 
Investigator Signature 
The signatures of the Principal Investigator (Pl) and representatives of Cetylite Industries,
Inc. (Cctylitc) below constitute their approval of this protocol and pnwidc the necessary
assurances Lhal this study will be conducted according lo all stipulations, dinically and
administratively, as detailed in the protocol, including all statements as to confidentiality.
It is agreed that the conduct and results of this study will be kept confidential and that the
CRFs and other pertinent data will become the property of Cetylite. 
It is agreed that the protocol contains all necessary infrmnation required to conduct the
study as outlined in the protocol, and that the study will not be initiated without the
approval of an appropriate Institutional Review Board or 
Independent Ethics Committee. 
It is agreed that all participants in this study will provide written informed consent in
accordance with the requirements specified in the FD/\ Regulations and the Current
International Conference on Harmonization Good Clinical Practice Guidelines. Ail
participants will also be informed that their medical records will be kept confidential
except for review by representatives of Cetytite, Institutional Review Board or other
University Offices, and the FDA and/or international regulatory authority. 
The following have reviewed and approved this protocol: 
Principal Investigator's Name : Elliot llcrsh, D.M.D., Ph.D. 
Medical Monitor's Signature: 
Medical Monitor's Name: Stephen A. Cooper, D.M.D., Ph.D. 
Sponsor Representative· s or President· s Signature: 
Sponsor Representative's Name: Gary L. Wachman, President 
November 10, 2016 Page 3 of 48 Date I 
Date 
Date 
Protocol vl0.4 
'••··f-Cetylite Industries, Inc. 
-.CONFIDENTIAL Amended (#3) Protocol C-002 IND # 117147 
. CTY-5339 Anesthetic Spray (CTY-5339-A)
Signature Page 
Investigator Signature 
The signatures of the Principal Investigator (PI) and representatives of Cetylite Industries, 
Inc. (Cetylite) below constitute their approval of this protocol and provide the necessary 
assurances that this study will be conducted according to all stipulations, clinically and 
administratively, as detailed in the protocol, including all statements as to confidentiality. 
It is agreed that the conduct and results of this study will be kept confidential and that the 
CRFs and other pertinent data will become the property of Cetylite. 
It is agreed that the protocol contains all necessary information required to conduct the 
study as outlined in the protocol, and that the study will not be initiated without the 
approval of an appropriate Institutional Review Board or Independent Ethics Committee. 
It is agreed that all participants in this study will provide written informed consent in 
accordance with the requirements specified in the FDA Regulations and the Current 
International Conference on Harmonimtion Good Clinical Practice Guidelines. All 
participants will also be informed that their medical records will be kept confidential 
except for review by representatives of Cetylite, Institutional Review Board or other 
University Offices, and the FDA and/or international regulatory authority. 
The following have reviewed and approved this protocol: 
Principal Investigator's Signature: Date 
Principal Investigator's Name : Elliot Hersh, D.M.D., Ph.D. 
Sponsor Representative's or President's Signature: Date 
Sponsor Representative's Name: Gary L. Wachman, President 
November 10, 2016 Page 3 of 48 Protocol vl0.4 
Cetylite Industries, Inc. 
f Amended (#3) Protocol C-002 IND# 117147 
CTY-5339 Anesthetic Spray (CTY-5339-A) 
lnvcsti 0ator Siunaturc le, "' Signature Page 
The signatures of the Principal Investigator (Pl) and representatives of Cetylite Industries, 
Inc. (Cetylite) below constitute their approval of this protocol and provide the necessary 
assurances that this study will be conducted according to all stipulations, clinically and 
administratively, as detailed in the protocol, including all statements as to confidentiality. 
It is agreed that the conduct and results of this study will be kept confidential and that the 
CRF s and other pertinent data will become the prope1iy of Cetylite. 
It is agreed that the protocol contains all necessary information required to conduct the 
study as outlined in the protocol, and that the study will not be initiated without the 
approval ofan appropriate Institutional Review Board or Independent Ethics Committee. 
It is agreed that all participants in this study \Vill provide ,vritten info1111ed consent in 
accordance with the requirements specified in the FDA Regulations and the Current 
International Conference on Harmonization Good Clinical Practice Guidelines. All 
participants will also be infonned that their medical records will be kept confidential 
except for review by representatives of Cetylite. Institutional Reviev,, Board or other 
University Offices. ,:md the FDA and/or international regulatory authority. 
L -------------·--------- -· 
Principal Investigator's Name: Elliot Hersh, D.M.D., Ph.D. 
Medical Monitor's Signature: 
Medical Monitor's Name: Stephen A. Cooper, D.M.D., Ph.D. 
Sponsor Representative's or President's Signature: 
Sponsor Representative·s Name: Gary L. \\/achman, President Date 
Date 
Date 
--- -- -------------------- ----- -··--·------·-
November 10, 2016 Page 3 of 3 Protocol v 10.4 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 4 of 48 Protocol v10.4 2.    TABLE OF CONTENTS 
1. STUDY PROTOCOL .................................................................................................1  
2. TABLE OF CONTENTS ...........................................................................................4  
3. CLINICAL PROTOCOL SYNOPSIS ......................................................................7  
4. STUDY FLOW CHART ..........................................................................................16  
5. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .......................19  
6. ETHICS .....................................................................................................................20  
6.1  Independent Ethics Committee or Institutional Review Board ......................20  
6.2  Declaration of Helsinki ...................................................................................20  
6.3  Subject Information and Consent ...................................................................20  
7. INTRODUCTION.....................................................................................................21 
8. RATIONALE, OBJECTIVES, OUTCOMES, AND HYPOTHESIS ..................23  
8.1  Rationale .........................................................................................................23  
8.2  Objectives .......................................................................................................23  
8.3  Outcomes ........................................................................................................23  
8.3.1  Primary Outcome Measures ...............................................................23  
8.3.2  Secondary Outcome Measures ...........................................................24  
8.4  Hypothesis ......................................................................................................24 
9. SUMMARY OF STUDY DESIGN ..........................................................................25  
9.1  Number of Subjects ........................................................................................26  
9.2  Inclusion Criteria ............................................................................................27  
9.3  Exclusion Criteria ...........................................................................................27 
10. CLINICAL SUPPLIES ............................................................................................28  
10.1  Study Medication and Dosage ........................................................................28  
10.2  Packaging and Labeling .................................................................................29 
10.3  Assignment of Study Medication ...................................................................30  
10.4  Administration of Study Medicati on and Duration of Evaluation .................30 
10.5
 Study Medication Accountability ...................................................................30  
10.5.1  Storage ..............................................................................................30 
10.5.2  Study Medication Inventory .............................................................30  
10.5.3  Return of Study Supplies ..................................................................31  
11. STUDY PROCEDURES ..........................................................................................31  
11.1  Study Conditions ............................................................................................31  
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 5 of 48 Protocol v10.4 11.2  Schedule of Assessments ................................................................................31  
11.2.1  Screening Assessments .....................................................................31  
11.2.2  Baseline Assessments .......................................................................32  
11.2.3  Post-Baseline Assessments ...............................................................32  
11.3  Efficacy Assessments .....................................................................................33  
11.3.1  Pin Prick Test (PPT) .........................................................................33  
11.3.2  Heat Sensation Tolerance .................................................................33 
11.4  Safety Assessments ........................................................................................33  
11.5  Blood Sampling, ECG and Pulse Oximetry ...................................................34  
11.6  Concomitant Medication ................................................................................34  
11.7  Study Participant Discontinuation ..................................................................34  
12. SAFETY ....................................................................................................................35 
12.1  Subject Examinations .....................................................................................35  
12.2  Subject Safety Information .............................................................................35  
12.3  Availability of Investigator .............................................................................35  
12.4  Adverse Events ...............................................................................................35  
12.4.1  Definitions ........................................................................................35 
12.4.2  Reporting Adverse Events ................................................................37  
12.4.3  Other Reportable Events ...................................................................38  
12.4.4  Adverse Event Recording and Reporting .........................................38 
12.4.5  Breaking the Blind ............................................................................39  
12.4.6  Discontinuation of Study due to an SAE ..........................................39  
13. STATISTICAL METHODS AN D DATA HANDLING .......................................39  
13.1  Sample Size Determination ............................................................................39  
13.2  Analysis Populations ......................................................................................40  
13.3  Demographic Data and Baseline Comparability ............................................40  
13.4  Data Adjustments and Derived Endpoints 
.....................................................40  
13.4.1  Time Windows .................................................................................40  
13.5  Statistical Methods for Efficacy Evaluations .................................................41  
13.6  Multiple End Points and Multiple Comparisons ............................................41  
13.7  Safety Analysis ...............................................................................................42 
14. STUDY ADMINISTRATION .................................................................................42  
14.1  Investigator Study Binder ...............................................................................42  
14.2  Subject Identification ......................................................................................42  
14.3  Case Report Forms .........................................................................................43 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 6 of 48 Protocol v10.4 14.4  Monitoring of Study .......................................................................................43  
14.5  Protocol Modifications ...................................................................................43 
14.6  Discontinuation of Study by Sponsor or PI ....................................................44  
14.7  Disclosure of Data/Publications .....................................................................44  
14.8  Informed Consent ...........................................................................................44  
14.9  Institutional Review........................................................................................44  
14.10  Retention of Records ......................................................................................45  
14.11  Responsibilities of Prin cipal Investigator .......................................................46  
14.12  Filing of Protocol with FDA...........................................................................47 
15. TEXT REFERENCES .............................................................................................48  
 
 
List of Tables  
Table 1- List of formulation co mponents; CTY-5339 and Placebo Spray………...22 
Table 2- Study Medications…………………………………………………………...28 
   
  
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 7 of 48 Protocol v10.4 3. CLINICAL PROTOCOL SYNOPSIS 
TITLE: A double-blind, partial cro ss-over, incomplete fact orial study to assess 
the local anesthetic efficacy and safety of CTY-5339 Anesthetic Spray 
(CTY-5339-A) when applied to th e cheek mucosal tissue in normal 
volunteers 
STUDY NUMBER: C-002 
PRINCIPAL 
INVESTIGATOR : Dr. Elliot V. Hersh, Director Clin ical Pharmacology Research Unit, 
Dept. of Oral and Maxillofacial Surgery/Pharmacology, University of Pennsylvania, School of Dental Medicine 
SITE: University of Pennsylvania, School of Dental Medicine 
240 South 40
th Street, Robert Schattner Center, Philadelphia, PA 
19104. 
STUDY OBJECTIVES: This study is designed to  assess the efficacy a nd safety of locally 
applied CTY-5339 Anesthetic Spray compared to 14.0% benzocaine alone in normal volunteers using experimental sensation including 
pinprick with a needle (PPT) and heat  sensation threshold (QST).  The 
objective of this study is to demonstr ate that the combination of the two 
constituents in the CTY-5339 Anesthetic Spray (CTY-5339-A) provides longer acting local anesthes ia than 14.0% benzocaine alone 
(CTY-5339-CB).  The primary objectiv e is to demonstrate that the 
CTY-5339-A one-spray dose is superior to CTY-5339-CB.  The secondary objective is to demons trate that the CTY-5339-A up to two 
sprays is a safe dosage. 
HYPOTHESIS: CTY-5339-A when locally applied to  cheek mucosal tissue in the 
mouth will have an onset comparab le to the fastest constituent, 
benzocaine, and a prolonged effect comparable to the longest acting constituent, tetracaine, of the comb ination product.  The study also is 
designed to demonstrate that both the CTY-5339-A one- and two-spray dosages are safe.  (The assumption be ing made is that benzocaine has a 
faster onset of action than tetracaine.) 
  
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 8 of 48 Protocol v10.4 STUDY 
DESIGN: 
                                 STUDY This is a single-dose, partial cros s-over, double-blind and single-center 
study with an active control treatment .  All subjects wi ll remain at the 
study center for each of the two 60 mi nute test sessions.  The subjects 
will be tested at two different te st sessions separated by 4-14 days. 
The study will include 76 subjects w ho will be evaluated for 60 
minutes at each test session. At each  session, a circular area of 
approximately one inch in diameter will be isolated on one side of the 
inner cheek using an indelible oral pencil.  Each session will use a different side of the cheek.  The pos sible sequences of  treatments with 
the metered spray at the two sessions are: 
Session 1 Session 2 
Formulation Sprays Formulations Sprays 
CTY-5339-A 1 CTY-5339-CB 1 
CTY-5339-A 2 CTY-5339-CB 1 
CTY-5339-CB 1 CTY-5339-A 1 
CTY-5339-CB 1 CTY-5339-A 2 
To maintain double-blind conditions , the CTY-5339-CB subjects in the 
two spray sequences will also recei ve one spray with the vehicle 
control (CTY-5339-P).  A third part y not involved with evaluating 
subjects will administer the drug.  The CTY-5339-P Vehicle will be 
sprayed outside the circumscribed area  to avoid dilution of active drug.  
Efficacy evaluations will be done at  1-5 minute intervals beginning 
immediately after drug administration and will include: 
Pin Prick (PPT) & QST Heat Sensation Tests: For PPT, evaluations will be done at 1 minute intervals for the first 5 
minutes to capture onset of anesthes ia.  Starting at 5 minutes after drug 
administration, both PPT and QST will be done at 5 minute intervals up 
to the one hour time point.  If ther e is no indication of  anesthesia by 10 
minutes, the subject will be considered a treatment failure and the assessment of PPT and/or QST, as a ppropriate, will be discontinued.  In 
addition, once onset of anesthesia has occurred, if there is no longer any anesthesia at two consecuti ve evaluation time points from 10 
minutes onward, the assessment of PPT  and/or QST, as appropriate, 
will be discontinued.   
Pin Prick Test (PPT) : The PPT will be assessed, using a 90-mm, 26-
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 9 of 48 Protocol v10.4 DESIGN: (cont) 
                                 STUDY 
DESIGN: (cont) gauge pencil-point spinal needle (Polymedic; Temena S.A., Bondy, France or equivalent).  At screening, 3 pin pricks will be performed on each cheek.  Pin pricks will be assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale (NRS).  In order to be eligible for the study, for each cheek, subjects mu st have a minimum score of “3” 
for the last 2 pin pricks, and one of t hose scores has to be “4” or higher. 
During each treatment session, at Baseline and at each post-dosing time point, 3 pin pricks will be performed first on the non-treated cheek and then on the treated cheek.  At Baseli ne, pin pricks on both cheeks will 
be assessed using a 0 (no pain) to 10  (severe pain) NRS.  Post-Baseline, 
pin pricks on the non-treated cheek will also be assessed using the 0 to 
10 NRS, but on the treated cheek, the three repetitions will be compared to the non-treated cheek as “No pain”, “Less Pain” or 
“Similar/More Pain”.  For each cheek, the first pin prick will not be used for analysis.  Of the remaining 2 pin pricks, the one with the most severe pain rating will be used fo r analysis.  During each treatment 
session, in order for a subject to be eligible to continue in the study, for each cheek, both of the last 2 Baseline  assessment pin pricks must have 
a minimum score of “3” for the last  2 pin pricks, and one of those 
scores has to be “4” or higher.  Post-Baseline, an assessment of “No 
Pain” or “Less Pain” at a drug application site will be recorded as presence of analgesia/anesth esia (“Responder”).     
Heat sensation threshold (QST-Heat) : The heat stimuli are delivered 
in 3 repetitions, with inter-stimul us intervals of  30s. The basal 
thermode temperature is set at a co mfortable 35ºC.  The rate at which 
the thermode heats up is set at 0.5ºC/s, while the rate at which it cools down is set at 8ºC/s. The maximum thermode temperature is set at 
51ºC. (Note: Hot beverages such as tea and coffee are frequently served 
at temperatures between 500C - 600C.  Burns can occur at 650C.25). 
Heat sensation threshold will be defi ned as the temperature at which the 
subjects first feel tingling,  warmth, heat, or pain.  
At screening, QST-Heat assessments will be performed on each cheek. In order to be eligible for the study, for each cheek, subjects must have 
a mean Heat sensation threshold of 48.5
oC or less,  based on the last 2 
of the 3 readings.  
During each treatment session, for each assessment, the first stimulus 
will be disregarded and the remaining two stimuli will be averaged for 
data analysis (unless the first two readings are 510C, in which case the 
third assessment will not be done) .  At Baseline and at each post 
treatment assessment, the heat sensation threshold will be performed on 
the treated cheek only.  During each treatment session, in order for a 
subject to be eligible to continue in the study, subjects must have a 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 10 of 48 Protocol v10.4 mean Heat sensation threshold of 48.5oC or less, based on the last 2 of 
the 3 readings.  Post-Baseline, the presence of analgesia/anesthesia will 
be defined when the heat sensation thre shold at the treated site is higher 
than the Baseline (“Responder”).  
All tests on the treated cheek will be done near the center of the 
circumscribed area, but in a slightly  different place at each consecutive 
evaluation time point.  All tests on the non-treated cheek will be performed at approximately the same part of the cheek as those on treated cheek.  
Randomization:  A randomization code will determine the sequence of 
treatments and to which circumscribed area the treatment is 
administered (left or right cheek).  Sensory testing will  be done in the 
following order: pin prick followed, where applicable, immediately by 
heat sensation tolerance.  
Subjects retain the right to withdr aw from the study at any time. 
EFFICACY 
MEASUREMENTS  The primary comparison of intere st is one spray of CTY-5339-A 
compared to one spray of CTY-5339-CB. Co-primary efficacy 
variables are duration of effect as  determined by PPT and duration of 
effect as measured by QST Heat.  Du ration of effect is defined as the 
time (in minutes) from onset to treat ment failure (for PPT, treatment 
failure occurs when an assessment of “Same/More” pain, and for QST, 
a treatment failure occurs when th e average heat temperature is the 
same or less than the average heat temperature at Baseline up to the 60-
minute time point (at two consecutive time points).   
The secondary efficacy variables include:  
 Duration of anesthesia (PPT and QST Heat) for the two sprays of 
CTY-5339-A compared to one sp ray of CTY-5339-CB plus CTY-
5339-P 
 Duration of anesthesia (PPT and QST Heat) for the two sprays of 
CTY-5339-A compared to one spray of CTY-5339-A 
 Onset of anesthesia for PPT and QST Heat 
 Percentage of responders for PPT and QST Heat for both onset and 
duration 
 Percentage of responders for PPT and QST Heat at each time point 
OTHER 
MEASUREMENTS  
 
  At Baseline and at the end of the 60-minute test session an ECG, vital 
signs, and a 7 mL blood draw w ill be taken.  The blood will be 
analyzed for the occurrence of s ubclinical methemoglobinemia by the 
HUP – Pepper Lab via co-oximetr y analysis. At screening and 
throughout each test session, subjects will also be monitored with pulse 
oximetry.  Methemoglobinemia is being defined as >5% of a subject’s 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 11 of 48 Protocol v10.4  
 hemoglobin in the methemoglobin state,  or a pulse oximetry reading of 
less than 91%.   
ESTIMATED 
DURATION OF SUBJECT 
PARTICIPATION 
IN THE STUDY:  The subjects will be tested on two separate occasions.  Each session 
will take approximately two hours total time; howev er, the actual 
efficacy testing will take 60 minutes.  There will be 4-14 days spacing between visits.  A phone follow-up will occur 3 days (± 1 day) and 15 days (± 2 days) after the subject completes Sessions 1 and 2, respectively.  If there are any advers e side effects, at the discretion of 
the PI, the subject may be asked to return to the study site for evaluation. 
DURATION OF STUDY: The study will be completed when the last subject completes the last follow up phone call.  The expecta tion is that the study will be 
completed within 4-6 months of the first subject entry. 
NUMBER OF SUBJECTS: Up to 150 male and female subjects will be screened in order to enroll up to 76 ASA Category I or II subjects.  The total number of exposures to study medication will be 152 (76 s ubjects x 2 exposures).  Each of 
the CTY-5339-A treatment regimens will have 38 exposures and the CTY-5339-CB will have 76 exposures. 
SAMPLE SIZE  
DETERMINATION: The sample size was selected based on evaluating a reasonable number of subjects to determine whether CTY-5339-A has a longer duration of 
action than CTY-5339-CB, which cont ains 14.0% benzocaine only.   
DOSAGE: 
(specific gravity is 
slightly less than 1; 
therefore 200 uL is an 
approximate volume.) CTY-5339-A 1-metered spay = 200 mg total ( ≈200  L) 
Benzocaine 28 mg + Tetracaine HCl 4 mg 
CTY-5339-A 2-metered spays = 400 mg total ( ≈400  L) 
Benzocaine 56 mg + Tetracaine HCl 8 mg 
CTY-5339-CB = 200 mg ( ≈200  L) 
Benzocaine 28 mg 
INCLUSION 
CRITERIA: a. Male and female subjects between 18-75 years of age with a Body Mass Index (BMI) ≤32; 
b. Subjects are ASA Category I or II and are in good physical health 
as judged by physical and laboratory examinations; 
c. Subjects with normal appearance of the oral mucosal tissues; 
d. At screening and at Baseline dur ing Session 1, subjects with PPT 
scores on both cheeks of at least “3” (on a 10 point NRS) on the last 
2 of 3 readings, 1of which must be a score of at least “4”;  
 
e. Subjects with mean QST Heat sensation temperature assessments 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 12 of 48 Protocol v10.4 on both cheeks of 48.5oC or less based on the average of the last 2 
of the 3 readings at screening or with a mean QST Heat sensation 
temperature assessment of 48.5oC or less based on the average of 
the last 2 of the 3 readings on th e treated cheek at  Baseline during 
Session 1;  
f. Subjects must agree to refrain from ingesting any systemic or 
topical analgesic medication for 3 da ys or 5 half-lives of the drug 
prior to and during each study session and alcohol for 1 day prior to 
and during each study session; 
g. Subjects must agree to refrai n from using mout h rinses, cough 
drops or throat lozenges on th e day of each test session; 
h. Female subjects must be physically incapable of childbearing potential (postmenopausal for more th an 1 year or su rgically sterile) 
or practicing an acceptable method of contraception (hormonal, barrier with spermicide, intrauteri ne device, vasectomized or same 
sex partner, or abstinence).  S ubjects using hormonal birth control 
must have been on a stable dose of  treatment for at least 30 days 
and received at least 1 cycle of treatment prior to randomization.  At Screening and at Baseline of both sessions, all females of childbearing potential must have a negative urine pregnancy test 
and not be breastfeeding; 
i. Negative urine drug screen for drugs  of abuse at Screening and at 
Baseline for each Study Session.  A positive drug screen result may 
be permitted if the subject has been on a stable dose of an allowed medication for >30 days;  
j. The subject is capable of read ing, comprehending, and signing the 
informed consent form. 
EXCLUSION CRITERIA: 
a. Subjects with a history of any signi ficant hepatic, renal, endocrine, 
cardiac, neurological, psychiatric,  gastrointestin al, pulmonary, 
hematologic, or metabolic disorder s, including glaucoma, diabetes, 
emphysema, and chronic bronchitis;  
b. Subjects with a history of any type of cancer other than skin related 
cancers; 
c. Subjects with conditions that affect  the absorption, metabolism, or 
passage of drugs out of the body, (e.g., sprue, celiac disease, Crohn’s disease, colitis, or liver, kidney, or thyroid conditions);  
d. Subjects with any history of alcohol or substance abuse (including a 
positive drug screen test); 
e. Subjects that currently have or have a history of uncontrolled  
hypertension; 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 13 of 48 Protocol v10.4 f. Subjects with a known hypersensitivity  to any local anesthetic drug; 
g. Subjects with a hematocrit leve l significantly below the normal 
range on the screening laboratory examination (as judged by the PI) 
or a pulse oximetry reading of less than 96% at screening or at 
Baseline of either session; 
h. Subjects with any clinically si gnificant abnormal lab result (as 
judged by the PI); 
i. Subjects with any condition or hist ory felt by the Investigator to 
place the subject at increased risk; 
j. Subjects who have smoked or chewed tobacco-containing substances within 6 months pr ior to the start of the study; 
k. Subjects judged by the Investigator  to be unable or unwilling to 
comply with the requirements of the protocol; 
l. Subjects who have used an investigational drug within 30 days prior to entering the study; 
m. Subjects who have donated blood within  3 months prior to the start 
of the study; 
n. Subjects who have previously participated in the trial; 
o. Subjects who are members of the st udy site staff directly involved 
with the study or a relative of  the Sponsor or other personnel 
involved with the study. 
ECG TIMES: ECGs will be taken at screening, and during treatment visits at Baseline (Time 0, within 1 hour prior to  drug administration) and then 
immediately after the 1 hour test session. 
SAFETY EVALUATION: 
 All potential subjects will receive a blood chemistry test and urine drug 
screen at the screening visit. As a safety precaution, at each study 
session, blood samples will be taken at Baseline and 1 hour after study 
medication to measure methemoglobin levels.   
Pulse oximetry will be performed at screening, and at each session at 
Baseline, and 10, 20,  30, 40, 50 and 60 minutes after drug 
administration. All the medications bei ng evaluated in this st udy are marketed local 
anesthetic products in the United States and are being used within their 
currently indicated dosages and indi cations. Adverse experiences will 
be recorded as they occur during the trea tment phase of the study and if 
voluntarily reported by the subject w ithin 3 days following completion 
of the first study session and within 15 days following the end of the subject’s participation in the study.   Treatment-emergent AEs will be 
summarized by incidence. The events will be coded using the Medical 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 14 of 48 Protocol v10.4 Dictionary for Regulatory Activitie s (MedDRA) and summarized by 
system organ class (SOC) and preferred term (PT). 
Irritation and/or infection at the site of application will be assessed.  
The severity, relationship to treatmen t, action taken, and outcome of the 
events will be documented.  The inci dence of all adverse events and 
drug-related adverse events will be evaluated.   In the event of any 
health related emergency, the clinical site will have a trained medical staff with a fully equipped emergency crash cart. 
STATISTICAL ANALYSIS: Primary Efficacy Endpoints: 
 Duration of anesthesia as measured by PPT for one spray CTY-
5339-A compared to the one spray CTY-5339-CB  
 Duration of anesthesia as measured by QST Heat for one spray 
CTY-5339-A compared to the one spray CTY-5339-CB 
Secondary Efficacy Endpoints: 
 Duration of anesthesia as measured by PPT and QST Heat for the 
two spray CTY-5339-A compared to the one spray CTY-5339-CB 
plus one spray CTY-5339-P 
 Duration of anesthesia as measured by PPT and QST Heat for the 
two spray CTY-5339-A compared to the one spray CTY-5339-A  
 Onset of anesthesia for PPT and QST Heat 
 Percentage of responders for PPT and QST Heat for both onset and 
duration 
 Percentage of responders for PPT and QST Heat at each time point 
Safety Data: 
 SBP, DBP, and HR at Baseline and at the end of each 60-minute 
test session, 
 Pulse oximetry at Baseline and at 10, 20, 30, 40, 50 and 60 minutes 
after drug administration,  
 12 Lead ECG at Baseline and at the end of each 60-minute test 
session, 
 Methemoglobinemia at Baseline a nd at the end of each 60-minute 
test session, and 
 Analysis of incidence and seve rity of all adverse events  
For the PPT, a “Responder” is define d based on an assessment of “No 
Pain” or “Less Pain” in response to the pain stimulus at each observation time when compared to the non-treated site, (See Appendix 
2).  The % of responders at each tim e point will be compared between 
treatments. In addition, the % of  subjects who have Onset (and 
Duration) will also be compared between treatments.   For the QST, a “Responder” is define d as follows: If the average heat 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 15 of 48 Protocol v10.4 temperature at each time point is greater than the average heat 
temperature at Baseline, then the s ubject at that time point will be 
considered a “Responder”.  The % of responders at each time point will 
be compared between treatments. In  addition, the % of subjects who 
have Onset (and Duration) will also be compared between treatments. 
Data will be generated as the difference in response between the 
control, non-treated site and the ac tive treatment site within in each 
subject. 
ANOVA and pairwise t-tests will be used to compare CTY-5339-A 
treatment groups to the CTY-5339-CB treatment group.  
  
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 16 of 48 Protocol v10.4 4. STUDY FLOW CHART 
 
TIME Informed 
Consent Medical 
 History Phys. 
Exam,  
ECG,  
Vital Signs, 
Pulse Ox Lab 
Tests, 
Drug 
Screen 
 Pregnancy 
Test 
Females Dosing 
 Pin Prick= P Heat Sensation Threshold= H 
(PPT & QST) Blood Draw AE 
Assessment 
Screening 
        P (both cheeks),          
H (both cheeks)   
Test 
Session 1     *   P (both cheeks),          
H (treated cheek)    
Test Session 2    *   P (both cheeks),          
H (treated cheek)     
-5 min          
0 hr             
1, 2, 3, 4 min       P (both cheeks)   
5, 15, 25, 35, 
45, 55 min        P (both cheeks),          
H (treated cheek)   
10, 20, 30, 40, 50 min   ***    P (both cheeks),          
H (treated cheek)   
60min        P (both cheeks),          
H (treated cheek)   
Discharge            
3 or 15-Day 
Call**          
* Urine Drug Screen Only **After Session 1, 3-Day Follow-up Call ± 1 day; After Session 2, 15-Day Follow-up Call ± 2 days 
*** Pulse Oximetry Only, if <91%, the subject will be discontinued from the study 
 P=pinprick evaluation; H=heat tolerance evaluation 
  
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 17 of 48 Protocol v10.4  APPENDIX 1: DESCRIPTION OF TESTING METHODS   
 Appendix 1A:  Pin Prick Test (PPT) 
Oral Mucosa sensation directly over the circ umscribed sites will be assessed with a 90-
mm, 26-gauge pencil-point spinal needle (Pol ymedic; Temena S.A., Bondy, France or its 
equivalent) at Screening, Base line and predetermined intervals after application of drug
.  
To standardize the methodology, all tests are performed by holding the needle at its hub 
and orienting it perpendicular to the oral muco sa surface.  Pressure is applied until the 
needle shaft bows slightly.  At screening a numerical score on a 0 – 10 pain intensity 
scale (NRS) is recorded for each cheek. After study drug administration, subjects are instructed to rate the pinprick sensation pe rceived over the circumsc ribed treatment site 
compared to that perceived at the contra-l ateral circumscribed, non-treated site and to 
report the sensation as none, less , or similar/more to the non-tr eated site.  Re ports of none 
or less indicate analgesia, while a report of similar/more indicates complete regression of analgesia.  At each observation, 3 pin pricks are performed first on the non-treated side, and then on the treated side.  For each cheek, the first pin prick will not used for analysis.  Of the remaining two pin pricks, the one with the most severe pain rating will be used for 
the data analysis.  
Appendix 1B: QST Heat Stimulus 
1. This procedure uses the QST Heat Stimulator, a commercially available thermo-
sensory analyzer (Medoc, 1 Ha’dekel, St. Ramat Yishai 30095, Israel) that 
delivers heat stimuli to the oral mucosa with a blunt thermode that is 6mm in 
diameter.  A central unit generates and transmits the signal to the thermode.  This 
signal is controlled by proprietary software stored on a laptop connected to the central unit.  Also attached to the centra l unit is a hand-held control (a computer 
mouse) that allows a study subject to st op the heating of the thermode.  As the 
temperature is increased, subjects are asked to report when they first start to feel a 
tingling, warmth, heat, or pain  sensation.  The subjects ar e instructed to turn off 
the heat probe by depressing the mouse when  they first start to feel tingling, 
warmth, heat or pain.  The heat is applied in graded increments until the subjects depress the mouse or the temperature reaches the maximum of 51
oC.  At the 
maximum heat of 510 C, the probe automatically turns off and tissue is not 
damaged.  (Note: Hot beverages such as tea and co ffee are frequently served at 
temperatures between 500 C- 600C.25)  
 
2. The heat stimuli are delivered, in three repe titions, with inter-stimulus intervals of 
30s. The basal thermode temperature is set at a comfortable 35ºC. The rate at which the thermode heats up is set at 0.5º C/s, while the rate at which it cools 
down is set at 8ºC/s.  The maximum ther mode temperature is set at 51ºC.  For 
each assessment, the first stimulus is discarded and the remaining stimuli are 
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 18 of 48 Protocol v10.4 averaged, unless the first two readings are 51ºC.  In this case, the third assessment 
is not completed.  At Baseline, and at each post-treatment time point, QST will be 
assessed on the treated cheek only.  
APPENDIX 2: CRITERIA FOR A “RESPONDER” 
PPT: 
Based on “No Pain” or “Less Pain” response to the pain stimulus at each 
observation time when compared to th e non-treated site, subjects will be 
classified as “Responders” or “Non Res ponders”.  At each observation, 3 pin 
pricks will be performed at each site (first on the non-treated cheek and then 
on the treated cheek).  The first pin prick will not be used for analysis.  Of the remaining two pin pricks, the one with the most severe pain rating will be used for the data analysis.  If the most severe pain rating at that time point is 
“No Pain” or “Less Pain”, then the subject  at that time point is a “Responder”.  
 
QST:  
The actual temperature data will be recorded at each time point.  Temperatures will be recorded for "first sensation of tingling, warmth, heat, or pain".  Scores will be censored at 51ºC, if no response is obtained. If the 
average heat sensation temperature at each time point is greater than the average heat sensation temperature at Baseline, then the subject at that time period will be considered a “Responder”.    
  
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 19 of 48 Protocol v10.4 5. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviation Definition 
AE Adverse event 
ANOVA Analysis of variance 
CFC Chlorofluorocarbons 
CFR Code of Federal Regulations 
CMH Cochran-Mantel-Haenszel 
CNS Central nervous system 
CRF Case Report Form 
DESI Drug Efficacy Study Implementation 
ECG Electrocardiogram 
FDA Food and Drug Administration 
GCP Good Clinical Practice 
GRAS Generally Recognized as Safe 
HCl Hydrochloride 
ICH International Conference on Harmonization 
IND Investigational New Drug 
IRB Institutional Review Board 
ITT Intent-to-Treat 
MedDRA Medical Dictionary for Regulatory Activities 
NF National Formulary 
NRS Numerical Rating Scale 
PI Principal Investigator 
PK Pharmacokinetics 
PPT Pin Prick Test 
PT Preferred Term 
QST Heat Stimulus Test 
SAE Serious Adverse Event 
SOC System Organs Class 
TESS Treatment Emergent Signs and Symptoms 
USP United States Pharmacopeia   
Cetylite  Industries,  Inc.       
CONFIDENTIAL  Amended (#3) Protocol. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 20 of 48 Protocol v10.4 6. ETHICS   
6.1 Independent Ethics Committee or  Institutional Review Board 
This protocol, informed consent form, and any amendments, will be submitted to local 
ethics committees or institutional review boa rds (IRBs) for review and approval.  A copy 
of the written approval or vote must be avai lable and sent to the Sponsor before study 
initiation.  Any amendment made to the appr oved protocol must be forwarded to and 
approved by the same ethics committees or IRBs before its imple mentation.  Regulatory 
authority notifications will also be in place and fully documented prior to study start. 
The Investigator and appropriate  representatives from the Spons or will sign the protocol 
to document their willingness to  adhere to this protocol and to conduct the study in 
accordance with the FDA guidelines and the In ternational Conference on Harmonization 
(ICH) guidelines for Good C linical Practice (GCP). 
6.2 Declaration of Helsinki 
This study will be conducted in accordance w ith the ethical principles that have their 
origin in the Declaration of Helsinki and c onsistent with good clin ical practice (GCP) as 
described by the United States Code of Federal Regulati ons (21CFR parts 50, 54, 56, and 
312) and by the ICH Guidelines, effective 17 January 1997. 
6.3 Subject Information and Consent 
Written informed consent, in accordance with local clinical investigation regulations, 
must be obtained from the subject (subjects must be 18 years of age or older) prior to 
participation in the study.  The Investigator  must provide a description of the study 
medication (including any potential and possibl e hazards) and the study procedures to the 
study subjects.  Information must be given both in oral and written form.  The subject 
information provided will be in English, and may not include any language that appears 
to waive any of the subject’s legal rights, or appears to release the Investigator, the 
Sponsor, the Sponsor’s representative, or th e institution, from liab ility or negligence. 
The Investigator will provide the prospective subject sufficient time to consider whether or not to participate, minimizing the possibili ty of coercion or undue influence, and will 
discuss any questions the subjects may have.  The Investigator will explain to the subject that withdrawal from the study is possible at  any time without detriment to care.  The 
Investigator will then ask the subject  to give consent in writing.   
The consent must include acknowledgment that medical records and medical data derived from the study may be forwarded to the Sponsor , to the Sponsor’s representative, to the 
FDA or other regulatory authorities.  Th e informed consent will follow the FDA 
Regulations and ICH Guidelin es, effective 17 January 1997. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 21 of 48 Protocol v10.4 7. INTRODUCTION 
Cetylite Industries, Inc. (Cetylite) is  a small pharmaceutical company based in 
Pennsauken, New Jersey.  The primary product for this company is a local anesthetic 
spray, Cetacaine® Spray, consisting of a combinati on of the three active ingredients 
benzocaine hydrochloride (HCl), tetracaine HC l, and butamben, USP.  The company also 
makes a liquid (solution) formulation with th e same constituents (with the exception of a 
CFC propellant).  The produc t has been grandfathered by the FDA under the DESI 
review and has been on the market in the US for approximately 60 years.  The current 
indications for Cetacaine® are: 
Cetacaine is a topical anesthetic indicated for the production of anesthesia of all 
accessible mucous membrane except the eyes. Cetacaine® Spray is indicated for use to 
control pain and gagging.  Cetacaine® Spray is indicated to c ontrol pain and for use for 
surgical or endoscopic or other procedures  in the ear, nose, mouth, pharynx, larynx, 
trachea, bronchi, and esophagus.  
As a result of the Federal mandate to eliminate CFCs and under current Federal 
Regulations and exemptions, Cetylite has to reformulate the spray formulation once its 
supply of CFCs is exhausted (estimated to between 2020 and 2022).  Since Cetacaine® is 
a grandfathered drug that never received an NDA approval; the FDA will now require an 
NDA for the reformulated product.  As part of the recent communica tion with the FDA, 
Cetylite has agreed to rem ove butamben from the product an d to reformulate a two-drug 
combination consisting of 14.0% benzocai ne, USP and 2.0% tetracaine HCl, USP 
delivered without CFCs. The new product is a metered spray designate d in this protocol 
as CTY-5339 Anesthetic Spray (CTY-5339-A).  
In Cetylite's most recent co rrespondence with the FDA in Ap ril of 2014, Cetylite outlined 
its proposed program for the conversion of Cetacaine® Spray containing CFC propellant 
to a non-CFC containing spray.  This le tter outlined a proposed new alternate 
formulation, a proposed animal  toxicology study and a clinical  program.  Since then the 
CTY-5339 formulation was developed without pr opellant as a metered dose pump spray.  
Cetylite has successfully completed a 28-day safety study in rabbits and will file the 
results of this safety study in their IND App lication to initiate human clinical trials.  
Summary of Critical Issues and Proposed FDA Questions 
One of the key issues for Cetylite is how th e development program translates to the final 
indications for CTY-5339 Anesthetic Spray.  The primary use for CTY-5339-A is for the 
induction of local anesthesia of mucous membranes to suppress the gag reflex during intubation procedures.  A secondary, but impor tant, use is for anesthetizing buccal and 
gingival tissues.  
Cetylite's proposed development program to the FDA consisted of the following: 
 A 28-day rabbit study using nasal mucosa (completed in April 2016). 
 A Phase II Cheek Mucosa study in normal volunteers- partial factorial design. 
 A Phase III Nasal Intubation study in normal volunteers- full factorial design. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 22 of 48 Protocol v10.4  A Phase III Gingival Surgery study in pa tients requiring gingival surgery- full 
factorial design. 
Based on the successful completion of this program, Cetylite anticipates: 
 Indications for use in  the nose, throat and buccal cav ity to suppress the gag reflex 
and pain sensation. 
 Indications for use in all oral muco sa tissues for surgical procedures. 
Cetylite's rationale for th is development program is: 
 Rabbit nasal mucosa is a highly sensitive and representative tissue type in human 
and provides an acceptable bridge to safety  in other mucosal tissues, i.e. throat 
and buccal cavity. 
 The Cheek Mucosa study will serve as the proof of concept study to evaluate the 
superiority of the combination in  comparison to benzocaine alone. 
 The Nasal Intubation study will serve as a representative of an airway model: 
 The Gingival Surgery study is designed to demonstrate efficacy in a surgical 
model. 
Table 1.  Compositions of CTY-5339-A, the Benzocaine-Only Comparator (CTY-5339-CB) and the Vehicle Control (CTY-5339-P) 
Ingredient Grade CTY-5339- (% w/w)
Aa CBb Pc
Benzocaine USP 14.0 14.0 - 
Tetracaine Hydrochloride USP 2.0 - - 
Dehydrated Alcohol USP 12.0 12.3 14.4 
Polyethylene Glycol 300 (PEG 300) NF 29.7 30.4 35.5 
Propylene Glycol USP 16.9 17.3 20.2 
Purified Water USP 18.0 18.4 21.5 
Benzyl Alcohol NF 5.0 5.1 6.0 
Benzalkonium Chloride Solution (50%) NF 0.5 0.5 0.5 
Saccharin Sodium USP 1.4 1.4 1.4 
Artificial Banana Flavor Food 0.5 0.5 0.5 
a CTY-5339-A: Active formulation containing both 14.0% benzo caine, USP and 2.0% tetracaine 
hydrochloride, USP.  Note: the term CTY-5339-A is used to designate the active formulation. 
b CTY-5339-CB: comparator formulation containing benzocaine, USP   
cCTY-5339-P: Vehicle formulation containing neither active ingredient 
In the proposed human experimental Cheek  Mucosal study in healthy volunteers, the 
CTY-5339-A or comparator CTY-5339-CB form ulations will be sprayed onto a 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 23 of 48 Protocol v10.4 circumscribed approximately one inch diameter area of the cheek.  The area will then be 
tested with pin prick (PPT) and heat (QST) to assess on set and duration of  effect.  The 
maximal (total) dose of CTY-5339-A that a subj ect can receive during this study is 56 mg 
benzocaine and 8 mg tetracaine HCl.  The expectation is that there will be very low 
systemic exposure of either benzocaine or tetracaine.  The doses being used in this study are within the prescribed doses listed on the current Cetacaine
® Spray label and are 
known to be safe doses of these local anesthetics.1-24 
The dose of benzocaine and tetracaine being employed in this study are indicated doses 
on the Cetacaine® label.  The PI has examined much  higher exposures to benzocaine (80 
mg – 200 mg) self-applied by patients to the oral mucous membranes and the offending 
tooth to treat toothache pain with relatively few minor adverse events recorded (no SAEs 
and no clinically discer nible methemoglobinemia).13 Likewise in the development of 
another product, the PI and hi s team have dosed subjects with  18 – 36 mg of tetracaine by 
the intranasal route to obtain maxillary tooth anesthesia with no SAEs reported (again this is 2 – 4 fold greater than the maxi mum tetracaine exposure on the current study.
8,10 
These three studies were approved by the University of Pennsylvania IRB. 
8. RATIONALE, OBJECTIVES, OUTCOMES, AND HYPOTHESIS 
8.1 Rationale 
The purpose of this study is to evaluate th e onset and duration of analgesia in humans 
when CTY-5339-A is sprayed onto intact cheek mucosal tissue.  If this proof-of-concept 
study is successful, then future studies wi ll evaluate CTY-5339-A in intubation and 
gingival surgical settings. 
8.2 Objectives 
The objectives of this study are to evalua te the onset and duration of CTY-5339-A 
compared to benzocaine only spray (CTY -5339-CB) in a human experimental pain 
model.       8.3 Outcomes 
8.3.1 Primary Outcome Measures  
 Duration of anesthesia as measured by PPT for the one spray of 
CTY-5339-A compared to the one spray of CTY-5339-CB   
 Duration of anesthesia as measur ed by QST Heat for the one spray 
of CTY-5339-A compared to the one spray of CTY-5339-CB   
8.3.2 Secondary Outcome Measures 
 Duration of anesthesia as measured by PPT and QST Heat for the 
two sprays of CTY-5339-A compar ed to the one spray of CTY-
5339-CB plus one spray of CTY-5339-P   
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 24 of 48 Protocol v10.4  Duration of anesthesia as measured by PPT and QST Heat for the 
two sprays of CTY-5339-A compared to the one spray of CTY-5339-A 
 Onset of anesthesia for PPT and QST Heat   
 Percentage of responders for PPT and QST Heat for both onset and 
duration 
 Percentage of responders for PPT and QST Heat at each time point 
8.4 Hypothesis 
The following hypotheses will be tested to an alyze the primary outcomes of the study: 
 The null hypothesis that the duration of anesthesia (PPT and QST Heat) for the 
one spray CTY-5339-A group is the same as the corresponding duration for the 
CTY-5339-CB one spray group will be tested against the alternative hypothesis that the means are not equal. 
The following hypotheses will be tested to anal yze the secondary outcomes of the study: 
 The null hypothesis that the duration of anesthesia (PPT and QST Heat) for the 
two spray CTY-5339-A group is the same as the correspondi ng duration for the 
CTY-5339-CB one spray plus CTY-5339-P one spray group will be tested against 
the alternative hypothesis that  the means are not equal. 
 The null hypothesis that the onset of anes thesia (PPT and QST Heat) for the CTY-
5339-A groups is equal to the corre sponding onset for CTY-5339-CB group will 
be tested against the a lternative hypothesis that the means are not equal. 
 The null hypothesis that the onset time until the first responder event (PPT and QST Heat) for the CTY-5339-A groups is equal to the corresponding onset time 
until a first responder event for CTY-5339- CB group will be tested against the 
alternative hypothesi s that the event tim es are not equal. 
 The null hypothesis that the duration time until the first non-responder event 
(QST and PPT) for the CTY-5339-A gr oups is equal to the corresponding 
duration time until the first non-responder event for CTY-5339-CB group will be tested against the alternative hypothesis  that the event times are not equal. 
The predicted outcome is that CTY-5339-A when locally applie d to cheek mucosal 
tissue in the mouth will have an onset co mparable to the fastest constituent, 
benzocaine, and a prolonged effect comparab le to the longest acting constituent, 
tetracaine, of the combination product.  The study also is designed to demonstrate that 
both the CTY-5339-A one and two-spray dosages  are safe.  (The assumption is made 
that benzocaine has a faster onset of action than tetracaine HCl.)  
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 25 of 48 Protocol v10.4 9. SUMMARY OF STUDY DESIGN 
This is a single-dose, double- blind and single-center stud y with an active control 
treatment.  All subjec ts will remain at the study center for each of the two 60 minute test 
sessions.  The volunteer subjects will be tested at two differe nt test sessions separated by 
4-14 days and serve as their own control. 
The study will include 76 subjects with 60-minute evaluations at each test session.  At each session, a circular area  of approximately 1 inch in diameter will be isolated on 
one side of the cheek.  Each session will use a different side of the cheek.  The possible 
sequences of treatments at the two sessions are: 
Session 1 Session 2 
Formulation Sprays Formulations Sprays 
CTY-5339-A  1 CTY-5339-CB  1 
CTY-5339-A  2 CTY-5339-CB  1 
CTY-5339-CB  1 CTY-5339-A  1 
CTY-5339-CB  1 CTY-5339-A  2 
(To maintain double-blind conditions, the CTY-5339-CB subjects in two spray sequences 
will also receive one spray with the vehi cle control (CTY-5339-P) just outside the 
circumscribed area.  A third party not involve d with evaluating subj ects will administer 
the drug.)  
For PPT, evaluations will be done at 1-minute intervals following drug administration for 
the first 5 minutes to capture onset of an esthesia.  Starting at  5 minutes after drug 
administration, both PPT and QST will be done at 5-minute intervals up to the one hour time point.  Once onset has occurred, if th ere is no analgesia at two consecutive 
evaluation time points (from 10 minutes onward) , the session will be discontinued.  In 
addition, if onset of analgesia has not occu rred by 10 minutes post dose, the subject will 
be considered a treatment failure and no further assessments will be made. 
PPT: The PPT will be assessed, using a 90-mm, 26-gauge pencil-point spinal needle 
(Polymedic or equivalent; Temena S.A., B ondy, France or its equivalent).  At each post 
dosing time point, PPT will be assessed in 3 repetitions on the non-tr eated site using a 0-
10 Numerical Rating Scale (NRS) with “0” as no  pain and “10” as severe pain.  PPT will 
then be assessed in 3 repetitions on the treated site.  These assessments will be compared 
to the contra-lateral, non-treated site as “No pain”, “Less Pain” or “Similar/More Pain”.  
“No Pain” or “Less Pain” at an applicati on site will be recorded as presence of 
analgesia/anesthesia (“Responder”).  
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 26 of 48 Protocol v10.4 QST : The heat stimuli are delivered in 3 repeti tions, with inter-stimul us intervals of 30s. 
The basal thermode temperature is set at a comfortable 35ºC.  The rate at which the 
thermode heats up is set at 0.5 ºC/s, while the rate at which it cools down is set at 8ºC/s. 
The maximum thermode temperature is set at 51 ºC.  The first stimulus is disregarded and 
the remaining two stimuli are averaged for data  analysis.  In situa tions where a maximal 
analgesia/anesthesia effect is demonstrated in  the initial two repetiti ons, the QST test will 
not be repeated for the third repetition and th e data will be recorded as maximal effect 
(51oC) based on the first two repetitions. 
Heat sensation threshold will be defined as the temperature at which the subjects first 
start to feel tingling, warmth, heat, or pain.  All tests will be done n ear the center of the 
circumscribed area, but in a different place at  each evaluation time point.  For QST, the 
first time point after Baseline wi ll begin at 5 minutes after drug administration.  Subjects 
will have a hand held mouse that  turns off the heat probe when they first start to feel 
tingling, warmth, heat, or pain.  At the maximum heat level of 510 C, the heat probe turns 
off automatically.  With a brief exposure at 510 C, there is no damage to the mucosal 
tissue.25  
Randomization:  A randomization code will determine in which circumscribed area each 
treatment is administered (left or right ch eek).  Immediately pr ior to beginning each 60 
minute test session, both the c ontra-lateral cheek and the ch eek to be dosed will be 
evaluated with the PPT.  For QST, the screening assessments will be performed on both 
cheeks, while during each treatment Session, at  Baseline and all post- dosing time points, 
assessments will be performed on the treated cheek only.  
Subjects retain the right to withdr aw from the study at any time. 
The PPT and QST tests will be done near the center of each evaluation area but in a 
different place at each evaluation time point .  For PPT, the non-treated control cheek will 
always be tested before the treated area.  The testing will be done in the following order 
where applicable: PPT and then QST.   
A safety phone follow-up call will occur 3 days  (±1 day) after the Session 1 and 15 days 
(±2 days) following Session 2.  
9.1 Number of Subjects 
The study will include 76 completed subjects.  It is anticipated that up to 150 ASA 
Category I and II subjects will be  screened to obtain the 76 subjects needed for the study. 
9.2 Inclusion Criteria 
Individuals may be included in  the study provided they meet all of the following 
inclusion criteria:   
a. Male and female subjects between 18-75 y ears of age with a Body Mass Index (BMI) 
≤32; 
b. Subjects are ASA Category I or  II and are in normal physical health as judged by 
physical and laboratory examinations; 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 27 of 48 Protocol v10.4 c. Subjects with normal appearance of the oral mucosal tissues; 
d. At screening and at Baselin e during Session 1, subjects with PPT scores on both 
cheeks of at least “3” (on a 10 point NRS) on the last 2 of 3 readings, 1of which must 
be a score of at least “4”;  
e. Subjects with mean QST Heat sensation temperature assessments on both cheeks of 
48.5oC or less based on the average of the last 2 of the 3 readings at screening or with 
a mean QST Heat sensation te mperature assessment of 48.5oC or less based on the 
average of the last 2 of the 3 readings on the treated cheek at Baseline during Session 
1; 
f. Subjects must agree to refrain from inges ting any systemic or topical analgesic 
medication for 3 days or 5 half-lives of the drug prior to and during each study 
session and alcohol for 1 day prio r to and during each study session; 
g. Subjects must agree to refrain from usi ng mouth rinses, cough drops or throat 
lozenges on the day of each test session; 
h. Female subjects must be physically incapable of childbearing potential 
(postmenopausal for more than 1 year or su rgically sterile) or practicing an acceptable 
method of contraception (hormonal, barrier  with spermicide, intrauterine device, 
vasectomized or same sex partner, or ab stinence).  Subjects using hormonal birth 
control must have been on a stable dose of  treatment for at least 30 days and received 
at least 1 cycle of treatment prior to randomization.  At Screening and at Baseline of both sessions, all females of  childbearing potential must have a negative urine 
pregnancy test and not be breastfeeding; 
i.  Negative urine drug screen for drugs of abus e at Screening and at Baseline for each 
treatment session.  A positive drug screen re sult may be permitted if the subject has 
been on a stable dose of an allowed medication for >30 days;  
j. The subject is capable read ing, comprehending, and sign ing the informed consent 
form. 
9.3 Exclusion Criteria 
Individuals are not eligible fo r participation in the study if any of the following are noted:  
a. Subjects with a history of any significan t hepatic, renal, endocrine, cardiac, 
neurological, psychiatric, gastrointestin al, pulmonary, hematologic, or metabolic 
disorders, including glaucoma, diabet es, emphysema, and chronic bronchitis; 
b. Subjects with a history of any type of cancer other than skin related cancers; 
 
c. Subjects with conditions that affect the ab sorption, metabolism, or passage of drugs 
out of the body, (e.g., sprue, celiac disease, Crohn’s disease, colitis, or liver, kidney, 
or thyroid conditions);  
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 28 of 48 Protocol v10.4 d. Subjects with any history of alcohol or substance abuse (including a positive drug 
screen test); 
e. Subjects that currently have or have  a history of uncont rolled hypertension; 
f. Subjects with a known hypersensitivity  to any local anesthetic drug; 
g. Subjects with a hematocrit level signi ficantly below the normal range on the 
screening laboratory examina tion (as judged by the PI) or a pulse oximetry reading of 
less than 96% at scr eening or at Baseline of either session; 
h. Subjects with any clinically  significant abnormal lab re sult (as judged by the PI); 
i. Subjects with any condition or history felt by the Investigator to place the subject at 
increased risk; 
j. Subjects who have smoked or chewed tob acco-containing substances within 6 months 
prior to the start of the study; 
k. Subjects judged by the Investigator to be  unable or unwilling to comply with the 
requirements of the protocol; 
l. Subjects who have used an in vestigational drug within 30 days prior to entering the 
study; 
m. Subjects who have donated blood within 3 m onths prior to the start of the study; 
n. Subjects who have previously participated in the trial; 
o. Subjects who are members of the study site st aff directly involved with the study or a 
relative of the Sponsor or other personnel involved with the study. 
10. CLINICAL SUPPLIES  
10.1 Study Medication and Dosage 
The Sponsor will supply the following  study medication for administration: 
Table 2.  Study Medication 
Treatment Group Contents of Metered Spray Bottle 
CTY-5339 Anesthetic Spray 
1 spray (≈200  L total) 14.0% Benzocaine, USP = 28 mg 
2.0% Tetracaine Hydroc hloride, USP = 4 mg 
CTY-5339 Anesthetic Spray 
2 spray (≈400  L total) 14.0% Benzocaine, USP = 56 mg 
2.0% Tetracaine Hydroc hloride, USP = 8 mg 
CTY-5339-CB 
1 spray (≈200  L total) 14.0% Benzocaine, USP = 28 mg 
CTY-5339-P 1 spray (≈200  L total) Vehicle control (no active ingredient) 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 29 of 48 Protocol v10.4 10.2 Packaging and Labeling 
All study medication bottles will be labeled according to the FDA guidelines. In order to 
maintain the double-blind conditions for all treatment groups, the person(s) preparing and 
administering the test treatments will be diffe rent from the person(s) doing the clinical 
efficacy evaluations.  A randomization list ge nerated by the Statistics Group will list the 
investigational product(s) to be assigned to  each subject during each treatment session, 
and which cheek (left or right) the study medi cation should be applied to.  Subjects will 
be numbered starting from 101. 
 Study medication for subjects randomized to receive CTY-5339-A one spray in one 
treatment session and CTY-5339-CB one spray in the other treatment session will be 
double-blinded and packaged individually.  Study medication for each subject will 
consist of 2 bottles, one bottle containi ng CTY-5339-A, and one bottle containing CTY-
5339-CB. Each bottle will be labeled with the appropriate treatment session (A or B) and 
which cheek the study medication should be a pplied to (left or right), according the 
randomization schedule. The two bottles will be  packaged in a box.  Each bottle will be 
primed three times immediately prior to use. 
Study medication for subjects randomized to receive CTY-5339-A two sprays in one 
treatment session and CTY-5339-CB one spray and CTY-5339-P one spray in the other 
treatment session will be packaged in bulk.  The label for each bottle will contain the 
identity of its contents  (CTY-5339-A, CTY-5339-CB, or CTY-5339-P). The person 
preparing and administering the test treatme nts will use the randomization list generated 
by the Statistics Group to apply the appropriate product to th e appropriate cheek, and the 
appropriate area(s) of the cheek. The bottle will be primed three times prior to each use. 
Another randomized listing generated by Stat istics Group that has the same treatment 
assignments will be sent to the appropriate party responsible for packaging and labeling 
the study medications.   
In addition, a master code will be kept by the Sponsor and at the study site.  The study 
site master code will have individually se aled envelopes identifying the drug in each 
bottle for each patient enrolled  in the study.  The treatment for an individual subject may 
be unblinded in the event of an emergenc y and only if medically necessary without 
breaking the code for any other subject.  Procedures to be fo llowed for unblinding, 
notification responsibilit ies, and regulatory requirements are detailed in Section 12.4.5.   
10.3 Assignment of Study Medication  
Treatment assignments will be determined by a computer-generated randomization 
schedule maintained by the Statistics Group. 
The randomization schedule will randomly assi gn one of the four treatments (CTY-5339-
A one spray, CTY-5339-A two sprays, CT Y-5339-CB one spray, or CTY-5339-CB one 
spray plus CTY-5339-P one spray) to the appr opriate area(s) of the cheek mucosa.  For 
PPT assessments, the untreated, control area on the contra-lateral side will always receive 
the stimulus assessment first.   
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 30 of 48 Protocol v10.4 Randomization numbers will be assigned in a sequential order starti ng from 101.  A drug 
delivery team (different for the evaluators or other study personnel) will administer the 
treatments to the cheek mucosal area. 
The randomization number assigned to the su bject will be recorded in the CRF.  
10.4 Administration of Study Medicatio n and Duration of Evaluation 
Each subject entered into  the study will be given the randomly assigned study 
medications in the assigned circumscribed ar eas of the cheek mucosa at Baseline (Time = 
0 hour).  The duration of in-house treatment ev aluations will last up to 60 minutes.  The 
same team of coordinators and/or investigators will do all the evaluations.      
10.5 Study Medication Accountability 
10.5.1 Storage 
All materials for this study must be stored in  an area free from environmental extremes in 
a locked closet and with restri cted access.  A Cetylite represen tative will inspect the study 
medication storage area and discuss the study medication acc ountability system with the 
PI and site coordinators pr ior to shipment of the st udy medication to the site.  
10.5.2 Study Medication Inventory 
Upon receipt at the study site, the carton containing the study medi cation supplies will be 
stored unopened in the study medication storag e room.  At the study initiation, the PI or 
an appropriate designee, and a representativ e of Cetylite will conduct an inventory and 
complete the study medication inventory record.  The original will be sent to Cetylite, 
and the PI will retain a copy.  Any interim sh ipments will be inventoried by the PI or 
his/her designee.  For all in terim shipments, a study medica tion inventory record will be 
completed.  The original will be returned to Cetylite, and the PI will retain a copy. 
The PI or an appropriate designee, upon disp ensing the study medication, must record the 
information on a study medication dispensing /return log.  For accounting purposes and 
assessing subject compliance, a representa tive of Cetylite will review the study 
medication dispensing/return log, inventory the study medication, and inspect the storage 
facility at appropriate  time intervals thr oughout the clinical inve stigation, depending on 
the length of the study.  The PI must account  for any discrepancy and/or deficiency. 
10.5.3 Return of Study Supplies 
All unused study medication shipped for this clinical trial will be returned to  the Sponsor 
at the termination of the study.  At the conclusion of the st udy, the PI or an appropriate 
designee, and a representative  of Cetylite will inventor y all used and unused study 
medication.  The study medication inventory re cord for returned study medication will 
then be completed.  Cetylite will retain the original, and the Investigator will retain a 
copy for his files.   
 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 31 of 48 Protocol v10.4 All unused study medication will then be returned to: 
Cetylite Industries, Inc.  
9051 River Road Pennsauken, NJ 08110 Attention:  Returned Study Supplies Protocol No. C-002  
Upon receipt at Cetylite , a letter acknowledging the receip t of returned materials and a 
copy of the Study Medication Inventory Record will be sent to th e Cetylite Medical 
Monitor. 
11. STUDY PROCEDURES 
11.1 Study Conditions 
a. Only subjects who satisfy all inclusion a nd exclusion criteria and provide written 
informed consent may part icipate in the trial; 
b. Subjects will remain at the study site for up to 2 hours at each of two test sessions.   
c. Subjects will be tested in the same room  and by the same coordinator team at each 
evaluation time point during bot h 1hour test sessions.  
11.2 Schedule of Assessments    
11.2.1 Screening Assessments 
During the screening period, the PI or hi s designee will examine each subject and 
complete a checklist of the inclusion and ex clusion criteria (see Sections 9.2 and 9.3, 
respectively) in order to determine the subjec t’s eligibility.  The Investigator or study 
coordinator will enter the pertinent historic al information (including any medication 
taken recently) and clinical findings (inclu ding blood pressure) in the appropriate 
section(s) of the source documents. 
A Subject Screening Log (provided by Cetylite) w ill be maintained in the site central file 
to document all subjects screened for entry in to the study.  Subjects will be screened only 
once.  All subjects who meet the entrance cr iteria will provide written informed consent 
before participating in the study.  Subjects are required to read, comprehend, and sign the 
informed consent.  The screening pro cedure will also include evaluation of: 
a. PPT and QST heat sensation assessments of each cheek 
b. Vital signs (pulse rate and blood pressure  in supine or reclining position, body 
temperature) and pulse oximetry (must be ≥ 96%) 
c. Safety bloods including section Clinical chemistry (Sodium, Potassium, Creatinine, 
AST, ALT, Alkaline Phosphatase, LDH a nd Bilirubin), Hematology (Hemoglobin, 
Hematocrit, Thrombocytes, Erythroc ytes and Full blood differential) 
d. Urine drug screen and pregnancy test 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 32 of 48 Protocol v10.4 e. 12 lead ECG (PR, QRS, QT interval, heart rate and rhythm) 
Appropriate screening information for elig ible subjects who are assigned a subject 
number and receive study medication will be  transcribed onto the corresponding sections 
of the CRF.  The experiment must occur w ithin 30 days of the screening visit.  
The following will be noted and recorded on the CRF: 
 Date and time the drugs treatments were initiated and completed 
 Any vital signs obtained (require blood pressure)  
11.2.2 Baseline Assessments 
After confirming continued eligibility, Baselin e ECG, vital signs, and blood sample will 
be obtained.  In addition, tissue site evaluations will be performed.  The area of the 
treated cheek is circumscribed using an oral indelible pencil. Prior to drug administration, 
the presence or absence of pain after th e PPT (using a 90-mm, 26-gauge pencil-point 
spinal needle), will be ev aluated on both cheeks  Heat se nsation threshold (using QST) 
will be assessed in the circumcised area of the to-be-treated side of the cheek.  These baseline data will be recorded  on the CRF.  The drug will th en be administered onto the 
assigned circumscribed area.  In order for a subject to be eligib le to continue in the study, 
the last 2 of the 3 base line PPT scores must be at least “3 ” or higher, and 1 must be “4” or 
higher.  The mean of the last 2 of the 3 baseline temperature assessments must be 48.5
oC 
or less. 
11.2.3 Post-Baseline Assessments 
The time points of the post-baseline efficacy as sessment are detailed in section 9 of this 
protocol.   The PPT will be performed on both the control and treatment sites at each 
evaluation time point.  The QST will be perf ormed only at the treatment site for the post 
baseline evaluation time points. 
11.3 Efficacy Assessments 
11.3.1 Pin Prick Test (PPT) 
Oral mucosal sensation directly over contro l and drug sites will be assessed with a 90-
mm, 26-gauge pencil-point spinal needle (Pol ymedic; Temena S.A., Bondy, France or its 
equivalent) at Baseline and predetermine d intervals after application of drug.  To 
standardize the methodology, all tests are perf ormed by holding the needle at its hub and 
orienting it perpendicular to the oral mucosa surface.  Pressure is applied until the needle 
shaft bows slightly.  For each te st, the subject is instructed to rate the pinprick sensation 
perceived over the treatment sites compared to  that perceived at the contra-lateral non-
drug site, and to report the sens ation as none, less, or similar/ more to the treated site.  
Subjects will rate pain at the control site on a 0-10 Numerical Rating Scale with “0” as no 
pain and “10” as severe pain.  Reports of none or less at the treatment site indicate 
analgesia, while a report of similar/more indicates complete regr ession or absence of 
analgesia. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 33 of 48 Protocol v10.4 At each observation, 3 pin pricks are performed at  each site, first at the non-treated cheek 
and then at the treated cheek.  The first pi n prick is not used for analysis.  Of the 
remaining 2 pin pricks, the one with the most  severe pain rating is used for the data 
analysis.   
11.3.2 Heat Sensation Tolerance 
This procedure uses the QST Heat Stimulator, a commercially available thermo-sensory 
analyzer that delivers heat stimuli to the oral  mucosa with a blunt thermode that is 6mm 
in diameter.  A central unit generates and transmits the signal to the thermode.  This signal is controlled by proprie tary software stored on a la ptop connected to the central 
unit.  Also attached to the cen tral unit is a hand-h eld control that allo ws a study subject to 
stop the heating of the thermode.  The heat is applied in graded increments until the 
subject first reports either tingling, warmth, h eat, or pain or the temperature reaches the 
maximum of 51ºC (Note: Hot beverages such as tea and coffee are frequently served at 
temperatures between 500C - 600C.25)  
The heat stimuli are delivered, in 3 repetitions, with inter-st imulus intervals of 30s. The 
basal thermode temperature is set at a comfor table 35ºC.  The rate at which the thermode 
heats up is set at 0.5ºC/s, while the rate at which it cools down is set at 8ºC/s. The maximum thermode temperature is set at 51ºC .  The first stimulus is discarded and the 
remaining 2 stimuli are then averaged (unle ss the first two stimuli reach the maximum of 
51ºC).  All tests will be done near the center of  each circumscribed area, but in a different 
place at each evaluation time point.   
11.4 Safety Assessments  
Adverse events will be recorded when they are reported or observed.  The AE collection 
period will begin at the time the subject is initially screened and continue for 15 days 
after the subject’s last admini stration of study medication.  Only the PI will determine the 
relationship to study medication for each AE prio r to breaking the blind.  The information 
will be recorded on the appropriate study cente r CRF and outpatient di ary.   In addition, 
vital signs (DBP, SBP, HR) will be assessed at the beginning and end of each 60 minute 
test session. 
11.5 Blood Sampling, ECG and Pulse Oximetry 
A blood sample (7 mL) will be taken at sc reening for purposes of assessing normal 
values for the subjects.  Additional blood samples (7 mL each) will be taken at the 
beginning and end of each 60 minute test session to assess for the possible occurrence of 
subclinical methemoglobinemia.  An ECG also will be performed both at Baseline and 
after the 60 minute sessions.  Al l blood test analyses will be  performed by the laboratory 
at Hospital of University of Pennsylvania-Pepper Lab.  During each test session, subjects 
will also be monitored using pulse oximetry  at Baseline and at 10, 20, 30, 40, 50 and 60 
minutes. Methemoglobinemia is being defined as >5% of a subject’s 
hemoglobin is in the methemoglobin state or a pulse oximetry reading is below 91%.  
The 5% level is still below the threshold wher e any clinically observable signs (blue lips, 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 34 of 48 Protocol v10.4 chocolate-brown blood color or shortness of breath) would be seen.  The study will be 
discontinued if a pulse oximetry reading falls below 91% or if the level of 
methemoglobinemia reaches > 5% in any subject. 
11.6 Concomitant Medication 
No other medications expected  to confound the evaluation of  the study medication will 
be allowed prior to or during th e test sessions.  This includes,  but is not limited to, the use 
of any analgesics, oral rins es and mouth lozenges.  All concomitant medications used 
during the study will be recorded in the CRF. 
11.7 Study Participant Discontinuation 
A subject will be considered discontinued from the study at any time under the following 
circumstances and will be replaced: 
a. Any subject who violates any condition of the entrance criteria after having been 
entered into the study; 
b. Any subject who develops a confounding concomitant illness (as determined by 
the subject, research coordi nator or Investigat or), serious adve rse event, or a 
hypersensitivity to the study medication; 
c. Any subject who becomes uncooperative, doe s not adhere to the requirements of 
the study protocol, or refuse s to complete the study; 
d. Any subject who requires any concomitant  medication during the course of the 
study that could confound the study results; 
e. Any subject who for the last 2 of the 3 assessments has PPT scores of less than 
“3” and does not have at least 1 assessment of “4” or greater, or has a QST mean 
heat sensation assessment higher than 48.5oC based on the last 2 of the 3 
assessments at Baseline prior to the start of each Session. 
f. Any subject who has a methemoglobinemia (>5%) or a pulse oximetry reading 
below 91% during Session 1 or Session 2. 
If necessary, additional coded study medication will be provided to the study site for 
replacement subjects.  A representative of Cetylite will provide the replacement number 
to the study site. 
Subjects who discontinue due to an adverse ev ent will not be replaced.  All discontinued 
subjects will record no further assessments after their time of discontinuation, and any 
recorded efficacy data will be included in th e intent-to-treat (ITT) efficacy analysis but 
not in the evaluable subject analysis.  All subjects taking study me dication with follow-up 
safety data will be included in the safety analysis.  Details of the reason(s) why a subject 
has been discontinued from the study should be recorded in the appropriate section of the CRF. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 35 of 48 Protocol v10.4 12. SAFETY   
12.1 Subject Examinations 
To ensure the safety and well-being of each  subject entered into the study, the subject 
must first be examined by the PI or Sub-Inve stigator and medically cleared to participate 
as required by the protocol.  Each subject will be observed for adverse events (AEs) and 
will be required to report any adverse events that develop during the course of the study 
and for 15 days post-drug treatment.  If at  any time during the study, the subject has a 
serious adverse event (SAE) or abnormality, the subject must be withdrawn from the 
study and appropriate care  should be initiated. 
12.2 Subject Safety Information 
In accordance with the regulatory requirements regarding informed consent (21 CFR Part 
50 Protection of Human Subjects), the subj ect will receive a copy of the informed 
consent form when discharged from the clinic.  The informed consent form will include 
the information needed to contact the PI, al ong with a description of the study medication 
the subject may have received. 
12.3 Availability of Investigator 
Either the PI or an appropriate designee will be available to the subject at all times during 
the study and names and phone numbers of the PI and/or appropria te designee will be 
listed on the informed consent form. 
12.4 Adverse Events 
12.4.1 Definitions 
Adverse Event 
An adverse event (AE) will be defined as any untoward medical occurrence in a subject 
administered study medication.  The adverse event does not necessarily have to have 
causal relationship with the study medication.  An AE can therefore be an unfavorable 
and unintended sign (including an abnormal laboratory findi ng), symptom, or disease, 
which is a change from baseline and is temporally associated with the use of the study medication, whether or not it is consid ered related to th e study medication. 
 Severity 
The following definitions will be used for grading severity of adverse events: 
Mild - Either asymptomatic or subject is awar e of the sign, symptom or event, but 
it is easily tolerated. 
Moderate - Discomfort enough to cause interference with usual activity and may 
warrant intervention. Severe - Incapacitating with inability  to do usual activities. 
 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 36 of 48 Protocol v10.4 Causal Assessment 
The causal relationship between an AE and the study medication will be determined by 
the PI on the basis of his clinical judgment and the following definitions: 
 Associated:  There is a reasonable possibili ty that the AE may have been caused by 
the study medication.  This definition appl ies to those AEs that are considered 
definitely, probably, and possibly related to the use of the study medication. 
a. Definitely Related:  An AE that: follows a reasonable temporal sequence from 
administration of the study medication; follows a known response pattern to the 
study medication; and, when appropriate  to the protocol, is confirmed by 
improvement after stopping the study medi cation (positive de-challenge) and by 
reappearance of the reaction after repeat  exposure (positive re-challenge); and 
cannot be reasonably explained by known characteristics of the subject’s 
clinical state or by other therapies. 
b. Probably Related:  An AE that: follows a reasonable temporal sequence from 
administration of the study medication; follows a known response pattern to the 
study medication; and, when appropriate  to the protocol, is confirmed by 
improvement after de-challenge; and cannot be reasonably explained by the 
known characteristics of the subject’s clinical state or by other therapies. 
c. Possibly Related:  An AE that: follows  a reasonable temporal sequence from 
administration of the study medication a nd follows a known response pattern to 
the study medication but could have been  produced by the s ubject’s clinical 
state or by other therapies. 
 Not Associated:   
a. Unlikely: An AE that does not follow a reasonable temporal relationship after administration of the study medication or could have been produced by the 
subject’s clinical state or other therapies.  
b. Not related: An AE for which sufficient in formation exists to indicate that the 
etiology is unrelated to the study medica tion.  Two or more of the following 
variables apply: 
 The AE does not follow a reasonable tem poral sequence after administration 
of the study medication; 
 The AE is readily explained by the subject ’s clinical state or other therapies; 
 Negative de-challenge—the AE does not abate upon dose reduction or 
cessation of therapy (assuming that it is  reasonable to expect abatement of 
the AE within the observed interval). 
Serious Adverse Event 
A serious adverse event (SAE) is any untowar d medical occurrence that occurs at any 
dose and: 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 37 of 48 Protocol v10.4  Results in death; 
 Is life threatening; 
 Requires inpatient hospitaliza tion or prolongation of an existing hospitalization;  
 Results in persistent or significant disability/incapacity;  
 Is a congenital anomaly/birth defect. 
 Is a medically important condition: Importa nt medical events that may not result 
in death, be life-threatening, or require hospitalization may be considered a SAE 
when, based upon appropriate medical judgm ent, the event(s) may jeopardize the 
subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.   
12.4.2 Reporting Adverse Events 
Any SAE, regardless of causal relationship, must be reported immediately to the Medical Monitor at Cetylite  no later than 24-hours after awaren ess of the SAE.  Initial SAE 
reports may be made by telephone, and then  followed by faxing a completed “Serious 
Adverse Event Form” and confirming by telephone that the fax was received.  Compliance with this time requirement is esse ntial so that Cetylite may comply with its 
regulatory obligations.    
Contact: 
Medical Monitor:  
Name: Stephen A. Cooper, D.M.D., Ph.D.  
Address: 117 Dalena Way 
Palm Beach Gardens, FL  33410  
Telephone: 973-710-6677 
Fax: Same 
 
Follow up information relating to a serious adve rse event must be reported to the Medical 
Monitor and to Cetylite within 24 hours of receipt by the PI by faxing a completed 
“Serious Adverse Event Form” to Cetylite and confirming by telephone that the fax was 
received.  The subject will be observed a nd monitored carefully until the condition 
resolves or stabilizes and its cause is identified.  The PI also will promptly notify the appropriate Institu tional Review Board about th e serious adverse event.  
12.4.3 Other Reportable Events 
The following events will be recorded and reported in the same time frame and following the same process as for serious adverse events: 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 38 of 48 Protocol v10.4  Overdose or abuse of the study medication with or without adverse events (for 
this protocol, a total daily dose of benz ocaine exceeding 56 mg/day) or tetracaine 
exceeding 8 mg/day; 
 Inadvertent or accidental exposure to th e study medication with or without an 
adverse event. 
12.4.4 Adverse Event Recording and Reporting 
All AEs, whether serious or not, will be recorded on source documents and CRFs.  The 
recording period for AEs and SAEs starts at the time the subject is screened .  The 
recording period for both AEs and SAEs lasts through 15 days afte r the subject’s last 
administration of study medicati on, regardless of the relation ship to the study medication. 
The PI must follow up as medically necessa ry on all AEs, SAEs, and other reportable 
events until the event has subsided or values ha ve returned to baseline, or in the case of 
permanent impairment, until the condition stabilizes. 
For SAEs, the PI will provide all documentation pertaining to the event ( e.g. additional 
laboratory tests, consultation reports, discharge summaries, postmortem reports, etc.) to 
the Cetylite Medical Monitor in a timely manner.   Reports relative to  the subject’s course 
must be submitted to Cetylite until the event has subsided or, in the case or permanent 
impairment, until the condition stabilizes. Information about all adverse events, se rious and non-serious, including the event’s 
severity, start and stop times/ dates, chronicity, relatedness to study medication, and any 
actions taken, must be recorded on the appropr iate CRFs.  The information recorded will 
be based on the signs and symptoms det ected during the physical examination and 
clinical evaluation of the subject as well as information recorded in the subject’s diary, 
when applicable. 
12.4.5 Breaking the Blind 
A set of tamper-proof sealed  individual envelopes containi ng the bottle numbers on the 
outside of the envelope and the treatment code inside the envelope, will be sent to the 
investigative site.  In the event of a medi cal emergency that necessitates breaking the 
code, the sealed envelope containing the trea tment code may be opened.  The seal will 
only be broken by the Investigator in the ev ent of an emergency for which knowledge of 
the subject’s double-blind investigational produ ct will have a direct impact on treatment 
decisions.  Every effort will be made to disc uss the decision to break the blind with the 
Cetylite Medical Monitor in advance.  
When the blind is broken, the Investigator  will notify the Spons or’s Medical Monitor 
immediately in order to docum ent the reason and date of th e unblinding.  The event will 
also be recorded on the CRF and in the source document.  The Investigator will submit a 
written explanation to the Sponsor desc ribing the event within 5 business days. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 39 of 48 Protocol v10.4 12.4.6 Discontinuation of Study due to an SAE 
The study will be discontinued for safety reason s if a serious adverse event occurs in one 
subject unless it is demonstrat ed that the serious adverse ev ent is not related (as defined 
in section 12.4.1 of this protocol) to study drug, in which case the study will not be 
required to stop. 
The IRB will be notified within 24 hours of any event that results in discontinuation 
of the study. 
 
13. STATISTICAL METHODS AND DATA HANDLING 
The Statistics Group will perform statistical an alyses of efficacy data.  All computations 
will be performed using SAS® version 9.1 or higher (SAS Institute, Cary, NC).  
Statistical significance will be declared if the p-value is 0.05.   
Descriptive statistics for numerical variab les will include n (number of subjects 
involved), mean, standard deviation, median, minimum, and maximum values.  
Categorical variables will be desc ribed by number and percent.   
13.1 Sample Size Determination 
This study is a proof-of-concept study to de termine if CTY-5339-A one or two sprays 
have a relevant efficacy advantage over CTY-5339-CB.  Although a statistically significant difference is desirable, a clear-cu t trend for increased duration of analgesia 
would be acceptable.  A sample of 76 subjec ts in the efficacy evaluation part was felt to 
be adequate for the purposes of  this proof-of-concept study.   
13.2 Analysis Populations 
There will be three analysis populations: 
Safety population: will include all ra ndomized subjects w ho received the study 
medication.  This population will be  used for all safety summaries. 
Intent-to-Treat (ITT) population: will include  all randomized subjects who dosed with 
study medication and provided a Baseline assessment.  All secondary efficacy analyses 
and summaries will be performe d using this population.     
Modified Intent-to-Treat (mI TT) population: will include all randomized subjects who, as 
documented prior to the break ing of the study blind: (1) met all the inclusion and 
exclusion criteria and; (2) eith er completed the two 60 minute te st sessions or returned to 
baseline values in all the evaluation test s.  The primary efficacy analyses will be 
performed using this population. 
13.3 Demographic Data and Baseline Comparability 
Quantitative demographic data will be described by summary statistics (number of 
subjects, mean, standard deviation, median a nd range).  The number and percentage of 
subjects will be presented fo r categorical variables.  No formal statistical comparison 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 40 of 48 Protocol v10.4 between the treatment groups will be perf ormed.  Demographic data summary will 
include age, gender and race.  These data  will be presented fo r the overall safety 
population only, unless the sample sizes for ITT and mITT subject populations are very 
different from that of safety population (diffe r by more than 3 subjects).  In this case, 
demographic data will be presented for that population.  Baseline efficacy assessments 
will also be presented by treatment group. 
13.4 Data Adjustments and Derived Endpoints  
13.4.1 Time Windows  
Because some subjects may complete their assessments at times differing from the 
scheduled times, each such score will be adju sted so as to reflect more accurately the 
score that would have been obs erved had it been recorded at  the scheduled time.  With 
the exception of the 1-5 minute PPT evaluations, time windows will be created for each 
of the 5-minute scheduled PPT time points, the widths being 3 minutes.  The time 
window for the 1-5 minute PPT evaluations will be 30 seconds. 
 If an assessment is performed with in a time point window, the corresponding 
value will be assigned to that time point ( e.g., an assessment performed anywhere 
between 3 and 7 minutes from the previous  evaluation, regardless of when it was 
scheduled, will be assigned to the scheduled 5 minute time point).   
If a particular time point has no value within  its window, then the PPT  or QST Heat value 
with be assigned using either Last Obse rvation Carried Forward (LOCF) or Next 
Observation Carried Backward (NOCB). In particular, LOCF will be used for missing 
data prior to onset, and NOCB will be used for missing data after onset to conservatively estimate both onset and duration. 
13.5 Statistical Methods for Efficacy Evaluations 
The primary efficacy analyses will be based on Modified Intent-to-Tr eat Population.  The 
key comparisons will include: 
1. CTY-5339-A, one spray vers us CTY-5339-CB, one spray 
The co-primary efficacy variables are duratio n of effect as measured by PPT and QST 
Heat.  Duration of effect is defined as th e time (in minutes) from onset to treatment 
failure (i.e., for PPT, an asse ssment of “Same/More” pain, and for QST, the average heat 
temperature is greater than the average heat temperature at Baseline (non-treated cheek), 
up to the 60-minute time point (at two consecu tive time points). For those discontinuing 
from the study for any other reason, the time to treatment failure will be censored at the 
last assessment time.   
The secondary efficacy variables include:  
 Duration of effect (PPT and QST) fo r CTY-5339A two sprays versus CTY-5339-
CB, one spray plus CTY-5339-P one spray 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 41 of 48 Protocol v10.4  Duration of effect (PPT and QST) fo r CTY-5339A two sprays versus CTY-5339-
A one spray 
 Onset of anesthesia in minutes for PPT and QST Heat 
 Percentage of responders at each time point  for PPT and QST Heat for both onset 
and duration 
Continuous variables will be analyzed via an ANOVA model with treatment effects at 
each of assessed time points.  Pairwise compar isons for variables related to percentages 
will be analyzed via chi square tests.  Th e 95% confidence intervals of the treatment 
differences will be presented using normal a pproximation with continuity correction, if 
appropriate.  Pairwise comparisons for time-to -event related variables will be analyzed 
via a log rank model with treatment effects.  Median time to event will be estimated and 
the 95% confidence intervals for the median will be presented, if appropriate. 
13.6 Multiple End Points and Multiple Comparisons  
Duration of Effect, as assessed by PPT and QST Heat are co-primary efficacy 
parameters.  In order to control the over all significance level for the two primary 
endpoints, the total alpha level of 0.1 is Bonferroni adjusted  to 0.10/2 = 0.05 (since this is 
a proof of concept study, the to tal alpha level of 0.1 instead of 0.05 has been selected).  
The study will be considered successful if  either of the two primary endpoints is 
statistically significant.  13.7 Safety Analysis 
The safety population will cons ist of all subjects who receive d the study medication and had 
follow up data. 
Adverse event (AE) analyses will include all AE s which initially occu rred, or worsened 
following tr eatment (i.e.,  treatment emergent signs and symptoms, TESS).  AEs will be 
summarized by the MedDRA pr eferred term and by system organ class and classified 
according to their severity (mil d, moderate, or seve re) and relationship (“Suspect” or “Not 
Suspect”) to study medication.   For the summary by severi ty, subjects who have multiple 
occurrences of the same AE will be classified accordi ng to the worst report ed severity of the 
AE.  Similarly, for the summary by relationship to  the study medicatio n, the AE will be 
classified according to the worst relationship.  
ECG data will be summarized and presented based on assessment category (“Normal”, 
“Abnormal, but not clinically significant” or “Abnormal, clinically significant”) by 
treatment group.  Changes in SBP, DBP, and methemoglobinemia rate from Baseline to 
60 minutes will be summarized by treatment group.  Pulse oximetry will be summarized 
at each time point by treatment group. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 42 of 48 Protocol v10.4 14. STUDY ADMINISTRATION 
14.1 Investigator Study Binder 
The Sponsor will supp ly to the PI an Investigator Study Binder that must be maintained at 
the study site, unless an alte rnative filing system is deem ed appropriate by the Cetylite 
representative.   
Included in this binder w ill be tabbed sections for main taining the following:  study 
identification and study site st aff signature list, monitoring visit record, protocol and 
amendments/admin istrative changes, curricula vi tae, Institutional Review Board 
documentation, informed co nsent form, product  receipt and acco untability forms, 
correspondence, subject screening record, and mast er subject log.  This binder must be kept 
current and be available for review by repr esentatives of the Spon sor and any official 
regulatory body. 
14.2 Subject Identification 
For purposes of confidentia lity and to maintain  anonymity, subject s will be assigned 
identification numbers.  Subject s will be numbered sequentially as they enter the study.  
Once subjects meet the entry criteria, they  will be assigned a randomization number 
corresponding to study medicat ion.  Subjects should be iden tified to the Sponsor only by 
their assigned number, initials and date of birth.  The PI or his designee will maintain a 
complete list of all subjects enrolled in the study with their current ma iling address on the 
master subject log.  Th is list is necessary should contact of subjects be required in the future. 
14.3 Case Report Forms 
Case report forms (CRFs)  provided by Cetylite will  be used to document all subject data and 
will be typed or prin ted legibly in black or blue ink.  Prior to submission to Cetylite the PI 
will review all CRFs and sign wh ere necessary.  It is importan t that the CRFs be completed 
in a timely manner for each su bject evaluation in order that th e progress and results of the 
study may be closely followed by the Sponsor.   Corrections to CRFs must not obscure the 
original entry; a single line through the original entry is suffic ient.  All corrections must be 
initialed and dated by the responsible individual. 
CRFs are to be completed and held for retrieval by a repr esentative of Cetylite, unless 
otherwise directed.  All study re cords must be retained in acco rdance with Section 14.10.  A 
study site may use forms of thei r own design, following approval of the form by  Cetylite, as 
source documents only. 14.4 Monitoring of Study 
The study will be monitored by re presentatives of Cetylite.   On -site visits will be made 
before the study begins, at regular intervals during the conduct of the study, and at the 
comp
letion of the study.  Comm unication by telephone, mail, and facsimile may also be 
used to supplement on-site visits. 
The representative of Cetylite  will inspect all CRFs and co rresponding portions of the 
subject's original office and/or hospital reco rds.  These inspections are for the purpose of 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 43 of 48 Protocol v10.4 verifying adherence to the protocol and determ ining the completeness and exactness of the 
data entered on the CRF an d study medication log. 
As a part of monitoring and inspection of th is study, the PI agre es that Cetylite, its 
employees or representatives, Institutional Review Board or In dependent Ethics Committee, 
as well as representatives of the FDA will have the right to inspect and review pertinent 
medical records relating to this trial.  In addition, informed consent documents signed by 
study participants will indicate approval to release their medical record s for review while 
maintaining their confidentiality.  
14.5 Protocol Modifications 
As the study progresses, any ne cessary additions or changes to  the protocol will be decided 
by mutual agreement of the PI and the Clinical/Medical Monito r.  An amendment to this 
effect will be submitted first to Cetylite for review and approval  and then to the Institutional 
Review Board for review and ap proval prior to implementation.  If the protocol change 
impacts the conduct of the study, the info rmed consent form wi ll be amended, as 
appropriate.  A protocol change to eliminate an  apparent immediate hazard to su bjects may 
be implemented immediately, pr ovided the reviewing Institutio nal Review Board is notified 
in accordance with 21 CFR 56 .104(c).  Otherwise, no devi ations will be  permitted.  
Approved amendments w ill become part of the protocol  and will be reported to the 
appropriate regulatory authority prior to implementation.  14.6 Discontinuation of Study by Sponsor or PI 
Cetylite reserves the right to discontinue the study for administrative reas ons at any time.  
All study medication and CRFs will then  be returned to the Sponsor.  
If the PI discontinues the stu dy prematurely, the PI will return all study medication and 
CRFs to the Sponsor and prov ide a written explanation as to why the study was ended. 
14.7 Disclosure of Data/Publications 
All information obtained during the conduct of th e study will be regarded as confidential.  
Agreement from Cetylite must be ob tained prior to disclosing any information relative to the 
study. 
Upon completion of the st udy, Cetylite may decide to pub lish the results wi th the PI in a 
recognized scientific journal and/or present the results (as a poster or or al presentation) at a 
meeting of a recognized scientific  association.  In order to sa feguard against disclosure of 
confidential information,  however, Cetylite requir es that it has the right to review any 
manuscript and/or abstract prior to submission .  A draft manuscript must be reviewed by 
Cetylite 60 days prior to submission of the final version to the j ournal.  Abstracts of 
presentations must be re viewed by Cetylite 15 days prior to submission .  Cetylite assures the 
PI that all manuscript s and abstracts will be reviewed promptly.   
14.8 Informed Consent 
Regulations require th
at written informed cons ent must be obtained for each subject prior 
to entry into the study.  Informed consent m eans the knowing consent of an individual, so 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 44 of 48 Protocol v10.4 situated so as to exercise free power of c hoice without undue inducement or constraint or 
coercion.  The informed consent form will incl ude all elements required by the FDA.  A 
copy of the consent form will be provided to the subject. 
The Investigator will provide Cety lite with a copy of the consent form as approved by the 
Institutional Review Board at University of Pennsylvania. 
The PI will ensure that this study is in full conformance with the principles of the 
Declaration of Helsinki (as amended in Tokyo, Venice, Hong K ong South Africa and 
Scotland) as well as GCP and ICH guidelines.  
14.9 Institutional Review 
Prior to initiating the study, the protocol and amendments, informed consent form, any 
advertisement, PI’s an d sub-investigators’ curriculum v itae, and investigational product 
brochure must be reviewed and approved by a properly constitut ed Institutional Review 
Board as required by the FD A and the International Conference on Harmonization 
Guidelines.   
The PI must certify to Cetylite  that the Institut ional Review Board meets all the legal 
requirements as specified by the FDA.  The Institutional Review Board must provide a 
signed and dated statement that the protocol , informed consent form, and other pertinent 
documents, such as recruitment advertisements (in any medium) have been approved by the 
Committee.  If the study continues longer than one year, re-approval must be obtained from the Institutional Review  Board on an annual ba sis.  The Institutional Review Board must be 
informed of any changes in re search activity including amendments to the protocol and/or 
informed consent form, advertisem ents, and serious adverse events. 
At the conclusion of the study, the PI must su bmit a summary of the study to the 
Institutional Review Board with a copy forwarded to Cetylite no later than 60 days after the 
study closeout visit. 
14.10 Retention of Records 
International Conference on Harmonization (ICH) and FDA re gulations require that all 
study records be kept in the fi les of the PI for two years fo llowing the date a marketing 
application is approved for the indication which was investigated, or if  no application is 
filed or if the application is withdrawn, two years after the investigation is discontinued 
and the regulatory authority is notified.  Additionally, the master subject log must be 
maintained for a minimum period of 10 years from the dates defined above.
  Cetylite will 
notify the PI of the above date.  No study documents may be destroyed or moved to a 
new location without prior wri tten approval from Cetylite.  
If at any time the PI is no longer able to main tain the required study records, or if the PI 
relocates or delegates custody of  the records to another, Cety lite must be notified in 
writing as soon as possible.  In any case, Cety lite retains the right to reclaim all study 
records.  If Cetylite reclaims the st udy records, the master subject log, which contains 
confidential information identifying and how  to contact the study subjects, will be 
provided to Cetylite in a sealed envelope labeled “confidential”. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 45 of 48 Protocol v10.4 The PI assumes the responsibility of  retaining the following records: 
a. Signed and dated protocol and amendments, written authorization to allow enrollment 
of potentially ineligible subjects or otherwise amend the protocol; 
b. Curriculum vitae of the Principal In vestigator and s ub-investigators; 
c. Investigational Product Brochure or full pr escribing informati on, instructions to 
Principal Investigator, or other information provided by Cetylite for conducting the 
clinical study; 
d. Records of receipt and disposition of all product supplies, including: 
 Dates and amounts of product received from Cety lite 
 Lot numbers or other identification 
 Dates and quantity dispensed and returned for each subject 
 Dates and amounts of product returned to Cetylite 
e. Institutional Review Board approval, corre spondence, interim reports, and final study 
summary; 
f. Documented informed consent for each subject 
g. Completed CRFs and diaries (if applicable ) for each subject including all source 
documents from which the CRFs were prepared 
h. Subject screening record indicating dis position of each subject and reason for 
exclusion when appropriate 
i. Master subject log indicating all subjects enrolled in the study with their current 
mailing address 
j. Detailed medical histories for each subj ect containing medica l history prior to 
enrollment with basic identifying informati on linking records to CRFs, results of all 
diagnoses made, therapy provided, any ot her data on subject's physical state 
k. Medical history during the study including do cumentation of enrollment, concomitant 
or concurrently administered therapy, observations on subject's condition during the study, any factors that might alter the effect s of the test product, adverse event or 
laboratory abnormality reports and follow-up where appropriate 
l. Copies of tests and/or examinations re sults required by the protocol, including 
laboratory normal values and accreditation, if  applicable 
m. Copies of interim and final reports issu ed to the Institutional Review Board or 
Cetylite 
n. Documentation of contacts between Cetylite and the PI and/or other st udy site 
personnel, including all correspondence 
o. Copies of any reports on serious adverse ev ents, death, or life-th reatening symptoms 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended (#3) Protocol C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 46 of 48 Protocol v10.4 p. Roster of all study personnel with their signatures and signed initials 
q. Monitoring visit record 
14.11 Responsibilities of Principal Investigator 
In agreeing to conduct this study, the PI a ssumes certain responsibilities mandated by 
FDA regulations: an Investigator  is responsible for ensuring  that an investigation is 
conducted according to the signed investigator  statement, the investigational plan as 
defined by the protocol, and ap plicable regulations; for protecting the rights, safety, and 
welfare of subjects under the Investigator's car e; and for the control of the products under 
investigation.  An Investigator will, in accord ance with the appropriate regulations, obtain 
the informed consent of each human subject to whom the product is administered.  The 
Investigator will retain all study documen ts as stipulated in Section 14.10.  The 
Investigator certifies that he/s he has not been disbarred by  any regulatory agency from 
conducting clinical trials. The Investigator will comply with the requirements outlined in the CFR final ruling, Financial Disclosure by Clin ical Investigators, effective February 2, 
1999. 
14.12 Filing of Protocol with FDA 
This protocol and data from this study may be subsequently filed with the U.S. FDA. 
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended Protocol No. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 47 of 48 Protocol v10.4 15. TEXT REFERENCES 
1. Adriani M.D, John.; Donovan Campbell, M.D. Fatalities following topical application of 
local anesthetics to mucous membranes.  JAMA 1956; 162: 1527-1530.  
 
2. Adriani J, Mehta D, and Naraghi M. Mixtures of Local Anesthetics - The Effectiveness of Combinations of Benzocaine, Butamben, and Tetracaine Topically.  Anesthesiology Review 
1981; 8: 15-19.  
 
3. Anninger, W, Forbes, B, Quinn, G, Schreiner, MS. The effect of topical tetracaine eye 
drops on emergence behavior and pain relief af ter strabismus surgery.  JAAPOS 2007; 11: 
273-6.  
 
4. Blaha, GR, Tilton, EP, Barouch, FC, Marx, JL. Randomized trial of anesthetic methods for 
intravitreal injections.  Retina 2011; 31: 535-539.  
 5. Bourolias, C, Gkotsis, A, Kontaxakis, A,  Tsoukarelis, P. Lidocaine spray vs tetracaine 
solution for transnasal fiber-optic laryngoscopy.  Am J Otolaryngol 2010; 31: 114-116.   
6. Chalam, KV, Murthy, RK, Agarwal, S, Gupta, SK, Grover, S. Comparative efficacy of 
topical tetraVisc versus lidocaine gel in cat aract surgery.  BMC Opthalmol 2009; 17: 7.  
 
7. Drivas, EI, Hajiioannou, JK, Lachanas, VA, Bizaki, AJ, Kyrmizakis, DE, Bizakis, JG. 
Cocaine versus tetracaine in septoplasty: a prospective, randomized, controlled trial.              J Laryngol Otol 2007; 121: 130-133.  
 8. Giannakopoulos, H, Levin, LM, Chou, JC, Cace k, AT, Hutcheson, M, Secreto, SA, Moore, 
PA, Hersh, EV. The cardiovascular effects and pha rmacokinetics of intranasal tetracaine plus 
oxymetazoline: preliminary findings.  J Am Dent Assoc 20 12; 143: 872-880.  
 9. Greenfield W, Hittelman E, and Glickman R. Evaluation of Anesthetic Agents on Human Mucous Membrane: Al Illustration Experimental  Protocol Using Computers.  NYS Dental 
Journal 1986: 22 - 28.  
10. Hersh EV, Pinto A, Saraghi M, Saleh N, Pulaski L, Gordon SM, Barnes D, Kaplowitz G, 
Bloom I, Sabti M, Moore PA, Lee S, Meharry M, He DY, Li Y. Double-masked, randomized, placebo-controlled study to evaluate the efficacy and tolerability of intranasal 
K305 (3% tetracaine plus 0.05% oxymetazoline) in anesthetizing maxillary teeth.  J Am Dent 
Assoc 2016; 147:278-87.   
 11. Hersh, EV, Cooper, SA, Segal, H, Greene, J. Analgesic onset time as a measure of topical anesthetic in efficacy in spontaneous toothache pain: a pilot study. J Clin Dent 1993; 4:52-54.  
 
12. Hersh, EV, DeRossi, SS, Ciarrocca, KN, Secreto, SA, Ghassemi, A. Efficacy and 
tolerability of an intraoral benzocaine patch in the relief of spontaneous toothache pain.         
J Clin Dent 2003; 14: 1-6.  
Cetylite Industries, Inc.                  
CONFIDENTIAL  Amended Protocol No. C-002  IND # 117147
CTY-5339 Anesthetic Spray (CTY-5339-A)
 
November 10, 2016 Page 48 of 48 Protocol v10.4 13. Hersh EV, Ciancio SG, Kuperstein AS, Stoopler ET, Moore PA, Boynes SG, Levine SC, 
Casamassimo P, Leyva R, Mathew T, Shibly O, Creighton P, Jeffers GE, Corby PM, 
Turetzky SN, Papas A, Wallen J, Idzik-Starr C, Gordon SM. An evaluation of 10 percent and 
20 percent benzocaine gels in patients with acute toothaches: Efficacy, tolerability and compliance with label dose administration directions.  J Am Dent Assoc 2013;  144: 517-526. 
 14. Kluemper, GT, Hiser, DG, Rayens, MK, Jay, MJ. Efficacy of a wax containing 
benzocaine in the relief of oral mucosal pain caused by orthodontic appliances.  Am J Orthod 
Dentofacial Orthop 2002; 122: 359-365 .  
15. Korsten HH et al., Long-lasting epidural sensory blockade by n-butyl-p-aminobenzoate in 
the terminally ill intractable cancer pain patient.  Anesthesiology 1991; 75:950-960.  
16. Malamed, Stanley F. Handbook of Local Anesthesia. 3rd ed. St. Louis: Mosby Year 
Book, 1990: 46-73.  
 
17. Noorily, AD, Noorily, SH, Otto, RA. Cocaine, lidocaine, tetracaine: which is best for 
topical nasal anesthesia?  Anesth Analg 1995; 81: 724-727.   
18. Noorily, AD, Otto, RA, Noorily, SH. Intranasal anesthetic effects of lidocaine and 
tetracaine compared.  Otolaryngol Head Neck Surg 1995; 113: 370-374.  
 
19. Rømsing, J, Henneberg, SW, Walther-Larsen, S, Kjeldsen, C. Tetracaine gel vs EMLA cream for percutaneous anaesthesia in children.  Br J Anaesth 1999; 82: 637-638.  
 
20. Rosa, AL, Sverzut, CE, Xavier, SP, Lavrador, MA. Clinical effectiveness of lidocaine 
and benzocaine for topical anesthesia.  Anesth Prog 1999; 46: 97-99.  
 21. Rosivack, RG, Koenigsberg, SR, Maxwell, KC. An analysis of the effectiveness of two 
topical anesthetics.  Anesth Prog 1990; 37: 290-292.  
 
22. Sveen, OB, Yaekel, M, Adair, SM. Efficacy of using benzocaine for temporary relief of 
toothache.  Oral Surg Oral Med Oral Pathol 1982; 53: 574-576.   
23. Tulga, F, Mutlu, Z. Four types of topical anaesthetic agents: evaluation of clinical 
effectiveness.  J Clin Pediatr Dent 1999; 23: 217-220.  
 
24. Yau, GL, Jackman, CS, Hooper, PL, Sheidow, TG. Intravitreal injection anesthesia--comparison of different topical agents: a prospective randomized controlled trial.  Am J 
Ophthalmol 2011; 151: 333-337. 
 
25.  Vallez, LN, Plourde, BD, Abraham, JP.  Numerical study on the temperature profiles and 
degree of burns in human skin tissue during combined thermal therapy.  Numerical Heat Transfer Applications 2015; 67: 921-933.  
 